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ABSTRACT 
SLEEP/WAKE ACTIVITY AND ENERGY EXPENDITURE IN OVERWEIGHT AND 
OBESE OBSTRUCTIVE SLEEP APNEA PATIENTS: A PRE- AND POST-CPAP 
COMPARISON 
Pamela A. McCullough 
July 27,2011 
Overweight and obesity is a major contributing factor in an estimated 70% of all 
obstructive sleep apnea (OSA) cases. Approximately five percent of the adult population 
has OSA, and the numbers continue to soar with the rising prevalence of obesity. As a 
primary therapy, continuous positive airway pressure (CPAP) has demonstrated 
improvement in many comorbities associated with both OSA and obesity. Although 
anecdotal and clinical references support increased energy, activity, and weight loss as a 
potential benefit of CP AP treatment, there remains little evidence to endorse CP AP as a 
significant weight-reduction measure for overweight and obese OSA patients. The 
purpose of this study was to examine sleep/wake activity and energy expenditure, pre-
and post-CP AP treatment, in adult overweight and obese patients with OSA. A 
prospective, observational, longitudinal study design was employed to assess 24-hour 
actigraphic measures of sleep/wake activity and energy expenditure prior and subsequent 
to CPAP therapy. Analysis of variance (ANOVA) using repeated measures was 
performed to identify overall differences between pre-CP AP and one week post-CPAP 
and pre-CPAP and one month and post-CPAP sleep activity, wake activity, and 24-hour 
IV 
energy expenditure. Sixty-nine subjects were consented, with a total of 35 subjects 
completing the study. Data analyses revealed statistically significant mean differences in 
sleep activity, wake activity, and energy expenditure from pre-CPAP to post-CPAP at 
one week and one month. At baseline, and continuing through one week post-CPAP and 
one month post-CPAP, the CPAP compliant group demonstrated less sleep activity, more 
wake activity, and expended more energy than the CPAP noncompliant group. This study 
concluded that CP AP use is a statistically significant factor affecting sleep activity time, 
wake activity time, and energy expenditure. Regardless of CP AP compliance and length 
of use, the entire post-CPAP group demonstrated more sleep activity, had less wake 
activity, and burned fewer calories. From a clinical perspective, the results of this study 
do not support the use of CP AP as a potential weight loss measure in overweight and 
obese OSA patients, and emphasize the need for the inclusion of behavioral weight 
management and weight loss strategies in an at-risk population for comorbid illnesses. 
v 
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Background and Significance 
Obstructive sleep apnea (OSA) is a sleep disorder that disproportionately affects 
individuals who are overweight or obese. Approximately five percent of the adult 
population has OSA, with overweight and obesity a major contributing factor in an 
estimated 70% of these cases (Young, Peppard, & Gottlieb, 2002). Diagnostically, OSA 
is characterized by repeated upper airway collapse during sleep with subsequent 
reduction or cessation of airflow for greater than 10 seconds, occurring at least five times 
per hour of sleep. Either complete or partial obstruction of the upper airway and airflow 
results in decreased oxygenation and arousal from sleep. The most common cause of 
apnea is obesity and associated adipose tissue deposits within the neck, compressing and 
narrowing the upper airway, which collapses when the dilator muscle tone is reduced 
during sleep (Dempsey, Veasey, Morgan, & O'Donnell, 2010). OSA is often suspected 
when snoring, gasping or choking episodes, disrupted sleep, morning headache, and 
daytime sleepiness is reported (Guilleminault & Bassiri, 2005). Furthermore, sleep apnea 
has been linked to increased risk of hypertension, heart attack, stroke, heart failure, 
insulin resistance, depression, fatigue, and sleepiness with related occupational and 
driving accidents (Kapur et aI., 1999; Phillips & Kryger, 2005; Punjabi & Beamer, 2005; 
Won & Robert, 2007; Young, Peppard, & Gottlieb, 2002). 
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Polysomnography (PSG) is the standard diagnostic testing procedure used to 
confirm OSA, which measures physiologic parameters during sleep. Traditionally, 
treatment of OSA depends on the severity, determined from PSG as a calculated apnea-
hypopnea index (AHI) or respiratory disturbance index (RDI). Conservative treatment is 
often the first line of therapy, with weight loss a primary recommendation. Weight loss 
has been shown effective in reducing apneic events, particularly in cases where weight 
gain coincided with worsening of apnea and related symptoms (Peppard, Young, Palta, & 
Skatrud, 2000; Phillips & Kryger, 2005). Lifestyle and behavioral modifications and 
sleep hygiene are typical conservative treatment recommendations and often include 
weight loss strategies, such as increased physical activity and reduced calorie diets. 
According to the Cochrane Database of Systematic Reviews, the success and value of 
these first line measures has not been established (Shneerson & Wright, 2007). While 
nasal continuous positive airway pressure (CP AP) as an effective form of therapy for 
OSA has been well documented, the treatment adherence and compliance as measured 
both subjectively and objectively using downloadable compliance meters remains 
problematic, despite known cardiovascular, metabolic and quality of life benefits 
(Grunstein, 2005; Phillips & Kryger, 2005; Weaver, 2001). 
Research has consistently demonstrated the ability of nasal CP AP therapy to 
improve overall sleep, daytime fatigue, sleepiness, concentration, attention, and mood in 
OSA (Grunstein, 2005; Weaver, 2001). There is evidence that CPAP treatment reduces 
hypertension, insulin resistance related to diabetes, inflammatory markers identified in 
cardiovascular and cerebrovascular disease, and leptin levels associated with obesity in 
OSA (Won & Robert, 2000). These studies fail to translate outcomes to weight loss for 
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OSA patients, regardless of favorable changes in obesity-related physiologic parameters 
and laboratory variables in OSA patients treated with CPAP. 
While the most common cause of OSA is obesity, the effectiveness of CP AP for 
weight reduction is not well studied and to date has yielded inconsistent results (Chin et 
aI., 1999; Loube, Loube, & Erman, 1997; Noseda, Kempenaers, Kerkhofs, Houben, & 
Linkowski, 1996; Peppard et aI., 2000; Redenius, Murphy, O'Neill, AI-Hamwi, & Zallek, 
2007). Outcome measures of improved sleep architecture, oxygenation, and sleep 
consolidation have been demonstrated during one or two nights of PSG while using 
CPAP (Phillips & Kryger, 2005). Other daytime objective and subjective measures of 
sleepiness and performance have yielded improvement post-CPAP, yet studies have not 
addressed the effectiveness of CP AP, nor the extent of improving overall objective 
measures of continuous sleep/wake activity and energy expenditure. There exists 
primarily anecdotal and clinical reference to increased energy and activity as a potential 
benefit of CP AP treatment. Research incorporating the use of portable actigraphy devices 
could address this research gap by objectively, conveniently, and cost-effectively 
measuring continuous 24 hour sleep/wake activity and energy expenditure in a patient's 
natural environment. Both the Actiwatch® and the Actical®, actigraphy devices, have 
the ability to objectively assess 24-hour sleep and wake activity and energy expenditure, 
respectively. 
Purpose 
The purpose of this study was to examine the influence of CP AP therapy on 24-
hour sleep/wake activity and energy expenditure in overweight and obese OSA adults, as 
measured by the Actiwatch® and Actical® devices. Specifically, this research measured 
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and tested for differences in 24-hour sleep/wake activity and energy expenditure prior 
and subsequent to initiating CPAP therapy. 
Conceptual Framework 
This research study involved physiologic variables and phenomena that were 
derived from the physical/natural science perspective; however, there was not an existing 
formal theory, framework, or model that contributed to the structural process 
diagrammed in the schematic model (Figure 1). Rather, a synthesis of the available 
literature, combined with over 15 years of clinical sleep experience and observation, 
guided the framework and provided the theoretical underpinnings. This conceptual 
framework, was inductively derived, loosely structured with less specific conceptual 
interrelatedness, not directly tied to explicit theory or theories, and offered a general 
guidance to the research question and hypotheses. 
Variables of significance to this research have been incorporated into the 
schematic model and include overweight/obesity (BMI), OSA (polysomnography-AHI), 
sleep activity (actigraphy), wake activity (actigraphy), energy expenditure (actigraphy) 
and CPAP compliance (internal compliance meter). In this research, the propositions 
linking these concepts, as currently diagrammed, include the relationships between 
overweight/obesity and OSA, how sleep fragmentation/disruption and daytime 
fatigue/sleepiness are associated with OSA, and how (respectively) these concepts link 
OSA to increased sleep activity and decreased wake activity, with a decrease in 24-hour 
total energy expenditure. The lower half of the diagram illustrates CP AP treatment, with 
CPAP compliance affecting sleep consolidation (less sleep fragmentation/disruption), 






OVer ... "elght -
Obesity 












Figure 1. Schematic model illustrating sleep/wake activity and energy expenditure pre-
and post-CPAP in overweight and obese obstructive sleep apnea patients. 
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how (respectively) these concepts negatively correlate CPAP treatment (and level of 
compliance) with sleep activity, and positively correlate CP AP therapy with wake 
activity and 24-hour total energy expenditure. 
Overweight/obesity 
Starting at the top of the Figure 1, overweight and obesity have been defined 
based on the National Heart Lung and Blood Institute established body mass index (BMI) 
guidelines for underweight «18.5), overweight (25-29.9), class 1 obesity (30-34.9), class 
2 obesity (35-39.9), and extreme obesity, class 3 (>40) (National Institutes of Health, 
1998; National Institutes of Health, National Heart, Lung, and Blood Institute, 2000). 
Obstructive sleep apnea 
For this study, OSA has been defined using the diagnostic criteria adopted by the 
American Academy of Sleep Medicine Task Force (1999), which includes five or more 
obstructed breathing events per hour of sleep combined with excessive daytime 
sleepiness (not explained by other factors), or at least two of the following (not explained 
by other factors): 1) choking or gasping during sleep; 2) recurrent awakenings from 
sleep; 3) unrefreshing sleep; 4) daytime fatigue/sleepiness; or 5) impaired concentration. 
A diagnosis of OSA includes clinical symptoms confirmed by polysomnographic 
findings demonstrating an AHI ~5, using the 2007 AASM scoring guidelines (Iber, 
Ancoli-Israel, Chesson, & Quan, 2007). 
Obesity and obstructive sleep apnea 
As diagrammed, the schematic model demonstrates a link from overweight/obesity 
to obstructive sleep apnea, and is supported by evidence that increased weight and 
obesity is one of the strongest identifiable risk factors for OSA (Guilleminault & Bassiri, 
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2005). While the link between OSA and obesity has been well recognized, the association 
is complex and not completely understood (Wolk & Somers, 2006). Collectively, the 
cluster of mediating factors related to increased sympathetic activity, inflammation, 
endothelial dysfunction, oxidative stress, and hypercoaguability are postulated 
mechanisms contributing to the link between OSA and obesity and associated 
cardiovascular risk and metabolic dysfunction (Jean-Louis et aI., 2008; Miller & 
Cappuccio, 2007; Penev, 2000); however, it has yet to be confirmed that obesity is a 
direct cause rather than just a component OSA. These findings support the bi-directional 
relationship between overweight/obesity and OSA as diagrammed. 
Fragmented/disrupted sleep 
Figure 1 illustrates relationships between OSA and fragmented/disrupted sleep and 
daytime fatigue/sleepiness, with independent linkages from OSA to fragmented/disrupted 
sleep and daytime fatigue/sleepiness. An additional link from fragmented/disrupted sleep 
to daytime fatigue and sleepiness is diagrammed, as well. It is the arousals and 
awakenings resulting from apneic events that underlie the relationship with 
fragmented/disrupted sleep, which is frequently subjectively reported by those with OSA. 
Objectively, a polysomnographic arousal is defined by the AASM (Iber et al., 2007) as at 
least 3 seconds ofEEG shifting from alpha or theta (wake) waveforms followed by 10 
seconds of continuous sleep preceding and following the change; whereas, an awakening 
is at least 30 seconds of alpha or theta (wake) waveforms (Iber et aI.). 
Daytime fatigue/sleepiness 
The most common complaint from those with OSA is daytime fatigue and/or 
sleepiness (Guilleminault & Bassiri, 2005; Weaver, 2001; Weaver & George, 2005). 
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These terms are conceptually different; however it is not the concern of this study to 
objectively operationalize these concepts. These are considered subjective reports most 
commonly associated with daytime symptoms of OSA and may range from feeling tired 
or drowsy to napping or falling asleep (Guilleminault & Bassiri). The relationship 
between OSA and sleep fragmentation and disruption is believed to result in daytime 
fatigue and/or sleepiness. It has also been postulated that the direct effects of hypoxemia, 
carbon dioxide retention, and sympathetic nervous system activation on visceral obesity, 
insulin resistance, and hypercytokinemia lead to daytime fatigue and sleepiness in OSA 
patients (Ryan, Taylor, & McNicholas, 2005; V gontzas et aI., 2000). 
Sleep and wake activity 
Sleep disruption and arousal are included in the constellation of 
pathophysiological manifestations of OSA and are usually objectively measured using 
polysomnography (American Academy of Sleep Medicine Task Force, 1999). For 
purposes of this study, activity refers to gross motor (physical) movements as measured 
using an accelerometer (actigraphy) to distinguish 24-hour activity during wake and 
sleep. Polysomnographically, sleep activity is measured using electroencephalographic 
(EEG) measures and scored based on EEG waveforms, rather than measuring physical 
sleep disturbance or movements (Iber et a1.). As measured by actigraphy, increased sleep 
activity in those diagnosed with OSA is associated with disruption and arousal during 
nighttime sleep resulting in greater total 24-hour sleep time. In terms of 
polysomnography, wake activity refers to alpha EEG waveforms consistent with wake. In 
this study, decreased wake activity in those diagnosed with OSA refers to less physical 
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movement and activity during the day with less total 24-hour wake time (measured by 
actigraphy) versus actual EEG wake activity. 
In the upper half of the proposed model, OSA depicts a relationship with 
decreased wake activity (decreased physical movement with less total 24-hour daytime 
wake) and increased daytime fatigue and sleepiness. Studies have revealed subjective 
sleepiness in those with OSA as measured by sleepiness scales (Roehrs, Carskadon, 
Dement, & Roth, 2005). Likewise, objective sleepiness has been demonstrated in OSA 
with controlled maintenance of wakefulness studies (MWT) and multiple sleep latency 
tests (MSLT) (Carskadon & Dement, 2005; Roehrs et al.). To date, there have been only 
a few studies conducted to assess unrestricted daytime physical activity in OSA patients. 
It seems conceptually reasonable that an individual with OSA who experiences sleep 
fragmentation and disruption resulting in daytime fatigue and sleepiness would be less 
physically active during waking hours, even without empirical data. Jean-Louis et al. 
(2008) and Penev (2007), as well as others (Guilleminault & Bassiri, 2005; V gontzas et 
al. 1994; Weaver & George, 2005), have at least hypothesized or provided anecdotal 
reference to these phenomena. 
Energy expenditure 
The sum of activity during sleep and wake can be translated to total daily energy 
expenditure, with weight management a balance of energy intake and energy expenditure. 
Energy intake is measured by total kilocalories of dietary or nutritional food and 
beverage consumed, while energy expended is measured by level of activity, inclusive of 
both sleep and wake. The three main components of energy expenditure include basal 
metabolic rate (BMR) and resting metabolic rate (RMR), dietary-induced thermogenesis 
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(DIT), and physical activity or non-resting energy expenditure (Summerfield, 2001). 
While metabolic rate and dietary thermogenesis have been studied in OSA patients for a 
single 24-hour duration under controlled metabolic chamber conditions (Major, Series, & 
Tremblay, 2007; Ryan, Love, & Buckley, 1995; Stenlof, Grunstein, Hedner, & Sjostrom, 
1996), this research is interested in non-resting energy expenditure or physical 
movements during sleep and wake, such as fidgeting, random muscle movements, 
activities of daily living, exercise, and other movements or activities that can be 
measured using actigraphy, over multiple days and translated to energy expenditure. 
Research involving OSA and energy expenditure was limited and offered no clear 
consensus on whether OSA increases or decreases sleeping EE in OSA patients. Daytime 
wake time has been even less well-studied, but anecdotally, is thought to be reduced in 
OSA patients as a result of sleepiness and fatigue (Ancoli-Israel, 2005). Overall, these 
limited findings do not provide substantive support of energy expenditure changes in 
OSA, and further highlight the need for research to address this knowledge gap. 
Continuous positive airway pressure 
Continuous positive airway pressure (CPAP), when used, leads to less fragmented 
sleep, improves variable oxygen desaturation and changes, and decreases cardiovascular 
workload and other forms of autonomic nervous system stimulation resulting in favorable 
cardiovascular outcomes (Doherty, Kiely, Swan, & McNicholas, 2005; Heitmann et aI., 
2004; Kaneko et aI., 2003; Pepperell et aI., 2002; Stoohs et aI., 1993), less 
cerebrovascular disease and better metabolic profiles (Babu, Herdegen, F ogelfeld, Shott, 
& Mazzone, 2005; Becker et aI., 2003; Chin et aI., 1999; Harsch et aI., 2003; Harsch et 
aI., 2004). Furthermore, CPAP has shown improvements in neuropsychologic and 
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cognitive dysfunction (Bardwell, Ancoli-Israel, Berry, & Dimsdale, 2001; Borak et aI., 
1996; Derderian, Bridenbaugh, & Rajagopal, 1998), sleepiness (Yamamoto et aI., 2000), 
depression (Means et aI., 2003; Schwartz, Kohler, & Karatinos, 2005), and impaired 
quality oflife (Jenkinson, Stradling, & Peterson, 1997; Sin, Mayer, Man, Ghahary, & 
Pawluk, 2002). 
The lower half of Figure 1 links CP AP compliance with less fragmented sleep and 
improved wakefulness, then links CP AP compliance to decreased 24-hour total sleep 
activity (measured in minutes via actigraphy) and increased 24-hour total wake activity 
(measured in minutes via actigraphy) . The model terminates with an increase in 24-hour 
energy expenditure (as measured in kilocalories via actigraphy). As depicted in Figure 1, 
it is hypothesized that there is an association between CP AP compliance and sleep 
activity, wake activity and energy expenditure. That is, those who are more compliant 
with CPAP are more likely to exhibit increased wake activity, decreased sleep activity, 
and greater energy expenditure. 
Actigraphy 
Twenty-four hour energy expenditure, in kilocalories, can be measured using the 
Actical® actigraphy device. Likewise, 24-hour sleep and wake activity can be measured, 
in minutes, using the Actiwatch® actigraphy device. Hedner et aI. (2004) reported 
actigraphy to be a novel approach for assessing sleep-wake activity in OSA patients; 
however, only a few studies have used actigraphy to address changes in total 24-hour 
sleep/wake activity or non-resting energy expenditure following CP AP treatment. 
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Hypotheses 
The purpose of this study was to examine the influence ofCPAP on sleep activity, 
wake activity, and energy expenditure in overweight (BMI > 25) and obese (BMI > 30) 
OSA (AHI ~5) adults. Sleep activity, wake activity and energy expenditure were 
measured on a group of overweight and obese individuals prior and subsequent to 
initiating CPAP therapy, testing for differences that exist before and after therapy over 
time. The framework developed guided this research and addressed each of the following 
three hypotheses (hypothesis 1 [HI], hypothesis 2 [H2], hypothesis 3 [H3]): 
HI) Subjects will have a significant decrease in 24-hour total sleep activity over time 
as a result of using CP AP therapy (measured by the Actiwatch®) 
H2) Subjects will have a significant increase in 24-hour total wake activity over time 
as a result of using CP AP therapy (measured by the Actiwatch®) 
H3) Subjects will have a significant increase in 24-hour total energy expenditure 
over time as a result of using CP AP therapy (measured by the Actical®) 
Summary 
The conceptual framework and corresponding schematic model illustrates a 
structural process that is grounded in the literature, based upon findings from prior 
studies, and drawn from clinical experience. While illustrated as a structural process, it is 
the linking of these concepts, which offered direction to developing the purpose of this 
research, formulating hypotheses, and guiding proposed data collection methods. The 
literature review and research findings offered sufficient underpinnings to support the 
conduct of the proposed study and further suggested additional empirical testing using 
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current models that link OSA with obesity, cardiovascular disease and metabolic 
dysfunction as a framework for larger prospective studies. 
The schematic model provided the concepts and framework to guide this research 
in examining sleep activity, wake activity, and total calculated energy expenditure in 
overweight and obese OSA patients before and after CP AP treatment using the 
Actiwatch® and Actical® devices. Overweight (BMI > 25) and obese (BMI >30) patients 
were the targeted population for this study, as their risk of comorbidities are greater than 
those non-overweight/obese OSA patients. As research has shown, OSA (AHI ;::5) leads 
to disrupted and fragmented sleep, which increases energy expended during sleep. This 
sleep disruption results in daytime fatigue and sleepiness, which may reduce 24-hour 
total wake time, as determined by physical movement using actigraphy. Because there are 
two-thirds more hours of wake time than sleep, decreases in total 24-hour energy 
expenditure (caloric expenditure) may be expected. Following CPAP treatment it would 
be expected that these OSA patients will experience less sleep disruption and 
fragmentation, resulting in less total nighttime sleep, lower energy expenditure during 
sleep, less daytime sleepiness and fatigue with increased wake time activity. As stated in 
the hypotheses, and following the schematic model, the net loss of energy expenditure 
during sleep should be well compensated for during waking hours, and result in an 





This review of the literature will be divided into sections relevant to the concepts 
and variables of interest to this study. This chapter will provide an initial overview and 
discussion of sleep, obstructive sleep apnea, continuous positive airway pressure and 
overweight/obesity. Sleep and wake activity and energy expenditure as the study outcome 
variables of interest will be included, followed by a separate sleep-related review of 
actigraphy as the primary measurement instrument for this study. A brief introduction 
about sleep and the consequences of inadequate sleep and sleep disorders will provide the 
foundation to support the importance of sleep for maintenance and promotion of physical 
and mental health. OSA will be discussed as one of the most prevalent sleep disorders 
and will include a review of OSA pathogenesis, symptoms, diagnosis, health risks and 
treatment. A separate section will be devoted to CPAP therapy, as the most commonly 
prescribed treatment for OSA, and will address issues pertaining to compliance and 
effectiveness. Because OSA is associated with overweight and obesity, this review will 
explore the current state of the science as it relates to the link between obesity and OSA, 
associated health consequences and weight loss approaches. Furthermore, as the primary 
variables of interest to this study, the literature will be examined to identify relationships 
between sleep activity, wake activity and energy expenditure in OSA. Lastly, actigraphy, 
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as the research instrument used to measure sleep/wake activity and energy expenditure 
will be included in the review. Each ofthese areas will be explored in depth, highlighting 
the most relevant research findings as it pertains to the present study of 24-hour sleep 
activity, wake activity, and energy expenditure in overweight and obese OSA subjects 
prior to and following CP AP therapy. 
Sleep 
Sleep comprises about one-third, or approximately eight hours, of a 24-hour day. 
The understanding of sleep has historically evolved from simple subjective observations 
to more objective measures of physiologic and behavioral functions, distinguishing 
normal sleep from abnormal sleep. Conceptually, sleep has shifted from an intuitive 
belief of a passive state of brain and body inactivity, somewhere between wakefulness 
and death, to a more highly organized view of sleep as a complex state which is both 
qualitatively and quantitatively different from wakefulness, and is initiated and 
maintained by specific physiologic and behavioral mechanisms (Dement, 2005). 
Sleep involves a balance between physiology (circadian cyclic activity involving 
homeostatic regulatory neurologic and hormonal processes) and behavior (sleep-wake 
schedules, diet and physical activity, along with environmental, societal and cultural 
influences and demands). Any disruption to either physiologic or behavioral processes 
may lead to insufficient sleep, sleep disruption and sleep disorders. Individual 
consequences associated with sleep disorders result from abnormal or inadequate sleep, 
and may include varying degrees of irritability, moodiness, fatigue, tiredness, sleepiness, 
somnolence, and lethargy with decreased motivation, attention, memory, and 
concentration. (Hodgson, 1991; Vaughn & D'Cruz, 2005). Furthermore, poor sleep and 
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sleep disorders have been shown to decrease productivity, reaction time, and attention 
span. Evidence has also linked poor sleep and sleep disorders to increased health risks 
such as obesity, hypertension, vascular disease, heart disease, stroke, and diabetes 
(Vaughn & D'Cruz). Depression, anxiety and substance abuse have also been associated 
with inadequate sleep (Lee & Ward, 2005). More recent studies have linked obesity to 
inadequate, restricted, or short sleep duration among various age groups and populations 
(Gangwisch, Malaspina, Boden-Albala, & Heymsgield, 2005; Hasler et aI., 2004; Patel, 
Malhotra, White, Gottlieb, & Hu, 2006; Spiegel, Tasali, Penev, & Van Cauter, 2004; 
Taheri, Lin, Austin, Young, & Mignot, 2004;). Additionally, safety issues related to 
sleep and sleepiness have been more widely recognized and publicized, primarily the risk 
of motor vehicle, commercial, and industrial accidents (Rosekind, 2006). 
Sleep is considered a basic need and as critical to health as nutrition and physical 
activity (U.S. Department of Health and Human Services [USDHHS], 2003). Even with 
substantial sleep knowledge, there exists pervasive illiteracy and ignorance as to the 
importance of sleep and the relationship between sleep, sleepiness, wake function, and 
performance capacity. This pervasiveness has persisted as a direct result of the failure to 
adequately translate existing scientific knowledge linking sleep, sleep disorders, and 
health to broad-based research programs, educational initiatives, clinical practice settings, 
and public health policy agendas (Institute of Medicine Committee on Sleep Medicine 
and Research Board on Health Sciences Policy, 2006; Walsh, Dement, & Dinges, 2005). 
Obstructive Sleep Apnea 
It has been estimated that 50 to 70 million Americans suffer with sleep disorders 
(USDHHS, 2003). Obstructive sleep apnea is just one of more than 70 sleep disorders 
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affecting 18 million Americans that disrupt normal sleep architecture and physiology, 
resulting in many individual and public health risks and consequences (National Sleep 
Foundation, 2002; USDHHS, 2003). These risks and consequences have generally been 
poorly translated to public health agendas. More recently, steps have been made toward 
this effort with the introduction of objectives related to OSA medical evaluation and 
long-term management, and sleep-related motor vehicle safety into the Healthy People 
2010 datasets (Healthy People 2010). 
Obstructive sleep apnea (OSA) is considered the most common of the sleep-
related breathing disorders. Early descriptions of OSA date back to the 1800s, with a well 
known reference to the Pickwickian Syndrome, named for Joe, an obese, excessively 
sleepy, snoring boy as described in 1836 by novelist Charles Dickens in the "Posthumous 
Papers of the Pickwick Club" (Dement, 2005). It was not until 1965 that OSA was 
medically diagnosed using polysomnography in patients with pickwickian syndrome 
(Dement), and not until 1970 that OSA was identified in non-obese individuals (Dement). 
Pickwickian syndrome is now most often referred to as obesity-hypoventilation syndrome 
which is characterized by obesity, snoring, plethoric complexion, cyanosis, peripheral 
edema, and right-sided heart failure. While OSA patients may have common features 
associated with pickwickian syndrome, the obesity-hypoventilation syndrome is 
classified separately and is considered the most severe form of sleep-disordered breathing 
(Phillips & Kryger, 2005, Dempsey, Veasey, Morgan, O'Donnell, 2010). Sleep-
disordered breathing generally ranges from severe obesity-hypoventilation syndrome to 
mild, simple and benign snoring. OSA is the most common of the sleep-related breathing 
disorders and is also used interchangeably with obstructive sleep apnea-hypopnea 
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syndrome (OSAHS). For purposes of this study, OSA encompasses the spectrum of 
obstructive apneas, hypopneas and respiratory disturbance associated with sleep. 
Obstructive sleep apnea is an obstruction in upper airway breathing during sleep. 
Apneas (and hypopneas) are brief periods of reduced or absent airflow resulting from a 
complete or partial upper airway collapse while sleeping. From epidemiologic studies 
based on the general population or community cohorts, the incidence of OSA has been 
estimated to be between two and four percent of middle-aged men and women, with men 
affected more frequently than women (Kripke et aI., 1997; Young et aI., 1993). In more 
recent years, an exhaustive epidemiologic review of the literature conducted by Young, 
Peppard, and Gottlieb (2002), found that up to five percent of adults in Western countries 
are likely to have OSA. While there are numerous studies of infants, children, adolescents 
and the elderly with OSA, the scope of this study is limited to adults, ages 18 to 65. 
Other factors significant to OSA prevalence rates include menopause, race and ethnicity. 
Bixler et aI. (2001) found that after menopause, the prevalence in women equals that of 
men. Increased risk and higher prevalence rates of OSA has also been found in African 
Americans, Latinos and Asians with craniofacial features identified as the primary 
contributing factor (lp et aI., 2001; Scharf et aI., 2004). 
Pathogenesis 
The pathogenesis of OSA primarily relates to repeated upper airway collapse as a 
result of sleep-related neuromuscular compensatory loss and abnormal upper airway 
anatomy, either caused by adiposity or craniofacial structure (Nguyen, Yim, & Malhotra, 
2007). Structurally, the upper airway consists of the nasopharynx, oropharynx, and 
hypopharynx. Collapsibility may be favored based on the size of the upper airway lumen, 
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inclusive of the tongue, pharyngeal walls, and adipose tissue. Posterior displacement of 
the mandible and inferior placement of the hyoid bone is often implicated in upper airway 
collapse (Miles, Weyant, Forrest, & Rockette, 1996). Clinically, these deformities are 
referred to as a small chin, overbite, or retrognathia. Schwab et al. (1995) identified the 
volume of soft tissue structures surrounding the upper airway as an important OSA 
factor, primarily the lateral oropharyngeal structures such as oropharyngeal muscles, the 
pharyngeal constrictors, adipose tissue, and lymphoid tissue. Both inflammation and 
edema of the soft tissues have been described as both a cause and effect of OSA (Miles et 
al.). Additionally, an oropharynx which has a longer anterior to posterior shape, and a 
shorter lateral orientation, is more likely to increase predisposition to upper airway 
narrowing, resistance, and collapse (Malhotra et al., 2002). Nasal obstruction further 
increases negative pharyngeal pressure, airway resistance and collapsibility, and may be 
related to deviated nasal septum, mucosal edema and inflammation. Although nasal 
obstruction is significant, the effect on OSA is variable and not considered primary 
(Pevemagie, Demeyer, & Claeys, 2005). Other causes of upper airway collapse include 
involvement of neuromuscular control, lung volume, ventilatory control instability, C02 
reserve and loop gain, arousal threshold, and neurotransmitters (Miles et al.); all of which 
are all relevant, but the complexity of physiological involvement is beyond the scope of 
this study for inclusion. 
Overall, the consensus is that OSA results from predisposing anatomical factors 
and structural features combined with a decrease in neuromuscular compensation during 
sleep. While anatomical structure is critical to evaluating OSA, it does not exclusively 
account for the severity of OSA. The primary risk factors for OSA include obesity with 
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android-type fat distribution in the neck and abdomen, crowded and narrow oropharynx, 
nasal resistance, mandibular deformity and retrognathia, male gender, menopausal 
women, and certain ethnicities such as African Americans, Latinos and Asians (Ramar & 
Guilleminault, 2007). Other risk factors include middle-age (40 to 65 years old) , 
smoking, alcohol and sedative use, snoring, mouth breathing, supine sleep position, and 
conditions causing macroglossia, stroke or neuromuscular disease, congenital 
abnormalities affecting craniofacial structure, and polycystic ovarian syndrome (Ramar & 
Guilleminault; Young et aI., 2002). A positive family history also increases the risk of 
OSA, with genetic predisposition related to obesity and inherited craniofacial features 
(Guilleminault & Bassiri, 2005). 
Symptoms 
Clinically, OSA includes both nighttime and daytime symptoms. Nocturnal 
symptoms tend to be more specific to OSA, whereas, daytime symptoms are often a 
result of disrupted sleep, regardless of the cause (Guilleminault & Bassiri, 2005; 
Dempsey, et aI., 2010). The most common nighttime symptoms or observations of an 
OSA patient include a pattern of loud snoring, alternating with brief pauses in breathing, 
and followed by gasping or snorting episodes and a brief aWakening. A spouse, family 
member, or bed partner usually provides the greatest insight into this characteristic 
nighttime pattern associated with OSA, with apneic episodes reported by about 75% of 
bed partners (Hoffstein & Szalai, 1993). Most OSA patients are unaware of these 
patterns; however, some patients may report varying degrees of restless or disrupted 
sleep, diaphoresis, dyspnea or choking sensations, esophageal reflux, nocturia, dry 
mouth, drooling, and bruxism (Guilleminault & Bassiri). 
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Daytime or wake symptoms of OSA primarily include reports of daytime 
sleepiness or fatigue. Sleepiness may range from mild drowsiness and occasional napping 
when disengaged and inactive, to more severe episodes of sleep while engaged or 
actively eating, talking, or driving. Whether sleepiness is mild, moderate, or severe, there 
is usually underlying insufficient sleep associated with OSA respiratory-related arousals 
and sleep disturbance. Many may also experience varying degrees of chronic sleep 
restriction and/or sleep deprivation. In addition to sleepiness, some patients with OSA 
describe changes in dexterity, concentration, attention, memory, andjudgment 
(Guilleminault & Bassiri, 2005; Weaver & George, 2005). Personality and mood changes 
have been reported, such as aggressiveness, irritability, anxiety, and depression 
(Guilleminault & Bassiri). Morning headaches have been described in about half of OSA 
patients (Paiva, Farinha, Martins, & Guilleminault, 1997). Decreased libido or impotence 
has been reported as well (Guilleminault & Bassiri). OSA has further been associated 
with cognitive impairment resulting in decreased work and academic performance, 
increased accidents, and diminished quality of life (Weaver & George; Gonsalves, Paiva, 
Ramos, & Guilleminault, 2004). 
Diagnosis 
Diagnosis of OSA is based on symptom presentation and confirmed with 
polysomnography (PSG). PSG is the standard outpatient diagnostic procedure conducted 
overnight or during a person's usual sleep hours. This testing quantitatively measures 
physiologic sleep parameters, inclusive of electroencephalogram (sleep/wake stages), 
electrooculogram (eye movements), submental electromyogram (chin movement), 
electrocardiogram (heart rate and rhythm), nasal and oral thermocouples/pressure 
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transducers (airflow), snore/noise transducers, chest and abdominal bands (respiratory 
effort), anterior tibialis electromyogram (leg movements), pulse oximetry (oxygen 
saturation) and video recording and audio monitoring. Computer software programs are 
utilized for sleep data acquisition and preliminary analysis. Sleep technologists perform 
patient hook up with the necessary placement of electrodes and sensors, which is 
followed by computer and biologic calibrations and recording. During data acquisition, 
the technologists monitor the patient and data closely, both by computer tracings of 
recorded physiologic activity and video/audio surveillance. The technologist also initiates 
(per physician protocol and order) and titrates continuous positive airway pressure 
(CPAP) treatment for those patients diagnosed with sleep apnea or sleep disordered 
breathing. A single PSG is usually sufficient for diagnosis (American Thoracic Society & 
Medical Section of the American Lung Association, 1989), and if OSA is severe enough, 
both diagnosis and treatment with CP AP can be accomplished in one night/stay (McArdle 
et ai., 2000). A second night/stay for positive airway titration is indicated for those 
patients with more moderate OSA or for those unable to be successfully titrated during 
their first night or stay (Wittig et ai., 1984). Using Rechtschaffen & Kales (1968) scale, 
sleep data can be scored and analyzed by the sleep technologist, and later reviewed and 
interpreted by the board certified sleep specialist. Although Rechtschaffen & Kales has 
been the standard for sleep (EEG) scoring for several decades, a new scoring manual for 
sleep and sleep-related events has been adopted by the AASM and is required for 
accredited sleep centers (Iber, Ancoli-Israel, Chesson, & Quan, 2007). Alternatives to 
PSG include portable oximetry and ambulatory home monitoring devices, which offer 
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advantages over the laboratory setting, however, have limited diagnostic parameters 
(Chesson, Berry, & Pack, 2003). 
Level of OSA severity has been somewhat ambiguous and is usually a clinical 
judgment derived from PSG and based on a calculated apnea-hypopnea index (AHI) or 
respiratory disturbance index (RDI). The AHI or RDI is the most commonly used criteria 
to establish a diagnosis of OS A and quantify the severity, and is determined by the total 
number of apnea and hypopneas divided by the number of hours asleep (Phillips & 
Kryger, 2005). Findings from the Sleep Heart Health Study (SHHS) generated the 
greatest consensus about defining apneic and hypopneic events (Sharar et aI., 2001; 
Phillips & Kryger). This longitudinal study included over 6000 middle- and older-aged 
individuals with cardiovascular disease who underwent in-home portable PSG (Sharar et 
aI.). Sharar et aI. defined apneas as an absence up to a 30% of baseline airflow for greater 
than 10 seconds, with hypopneas defined as a reduction up to 70% of baseline airflow for 
greater than 10 seconds. This definition further required a four percent or more oxygen 
desaturation associated with the apneas and hypopneas, but did not include sleep 
disturbance or arousal (Phillips & Kryger). These definitions have been more widely 
accepted due to cardiovascular predictability and reproducibility of findings (Phillips & 
Kryger) and have been adopted by the AASM and outlined in detail in their new scoring 
manual (lber, Ancoli-Israel, Chesson & Quan, 2007). The specific criteria for diagnosis 
ofOSAHS adopted by the American Academy of Sleep Medicine Task Force (1999) 
includes five or more obstructed breathing events per hour of sleep combined with 
excessive daytime sleepiness (not explained by other factors), or at least two of the 
following (not explained by other factors): 1) choking or gasping during sleep; 2) 
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recurrent awakenings from sleep; 3) unrefreshing sleep; 4) daytime fatigue; or 5) 
impaired concentration. Severity of apnea has also been a debated issue, with mild OSA 
between five and fifteen obstructed breathing events per hour of sleep (AHI ~5 and :S15), 
and moderate to severe greater than 15 apneas or hypopneas per hour of sleep (AHI > 15) 
mild sleep apnea (Bixler et aI., 2001; Young et aI., 1993 ; Young, Peppard, & Gottlieb, 
2002). 
Health risks 
Health risks associated with OSA have been cited as hypertension (Hu et aI., 
1999; Nieto et aI., 2000; Peppard, Young, Palta, & Skatrud, 2000; Wolk, Shamsuzzaman, 
& Somers, 2003), neuropsychologic and cognitive dysfunction (Bedard et aI., 1991; 
Engleman et aI., 2000), impotence (Guilleminault & Bassiri, 2005), motor vehicle crashes 
(Horstman, Hess, Bassetti, Gugger, & Mathis, 2000; Young, Blustein, Finn, & Palta, 
1997), cardiovascular disease (Schafer et aI. 2002; Sharar et aI., 2001), and stroke 
(Bassetti & Aldrich, 1999; Bassetti, Aldrich, Chervin, & Quint, 1996). OSA has been 
linked endocrine and metabolic disorders, such as type 2 diabetes mellitus (T2DM) 
associated with glucose intolerance/insulin resistance (AI-Delaimy, Manson, Willett, 
Stampfer, & Hu, 2002; Punjabi, Ahmed, Polotsky, Beamer, & O'Donnell, 2003; 
Reichmuth, Austin, Skatrud, & Young, 2005; V gontas, Bixler, & Chrousos, 2005) and 
increased leptin levels associated with obesity (Ip et aI., 2001; Spiegel, Tasali, Penev, & 
Van Cauter, 2004). Depression (Schroder & O'Hara, 2005; Shepertycky, Banno, & 
Kryger, 2005), decreased quality oflife (Baldwin, Griffith, & Nieto, 2001; Weaver, 
2000;), and increased health care costs (Kapur et aI., 1999) have been linked to OSA as 
well. 
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Morbidity and mortality has been reported in large observational studies, with 
several studies demonstrating a significantly greater risk for those with moderate to 
severe OSA as compared to the general population (Ancoli-Israel et aI., 2001; Kripke et 
aI., 1997; Lavie, Lavie, & Herer, 2005; Young, Peppard, & Gottlieb, 2002). Three of the 
most commonly referenced longitudinal studies that have demonstrated an association 
with OSA and increased cardiovascular morbidities include the Wisconsin Sleep Cohort 
Study (Peppard, Young, Palta, & Skatrud), the Nurses' Health Study (Hu et aI., 1999), 
and the Sleep Heart Health Study (SHHS) (Nieto et aI., 2000). These studies have all 
supported the link between systemic hypertension and OSA. Additionally, the incidence 
of pulmonary hypertension has been estimated between 17% and 53% and is most likely 
to occur in those with underlying heart or lung disease, or in cases of obesity-
hypoventilation syndrome (Bady, Achkar, Pascal, Orvoen-Frija, & Laaban, 2000; 
Niijima et aI., 1999) . Similarly, the prevalence of coronary artery disease in OSA 
patients ranges from 14% to 65% (Andreas, Schulz, Werner, & Kreuzer, 1996), with AHI 
shown to be an independent risk factor and predictor for coronary artery and ischemic 
heart disease (Peker, Hedner, Kraiczi, & Loth, 2000; Schafer et aI. 1999). As with 
coronary artery disease, the prevalence rate of heart failure in OSA patients is quite 
variable, from 12 to 54% (Javaheri, 2006; Peppard, Young, Palta, & Skatrud, 2000), and 
attributed mainly to large negative intrathoracic pressure increases and hypoxemic 
episodes during apneic events (Won & Robert, 2007). Lastly, the SHHS also found a two 
to fourfold increased odds of cardiac arrhythmias (bradyarrhythmias, premature beats, 
and atrial fibrillation) in patients with an AHI greater than 30 (Mehra et aI., 2006). 
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Vascular risks associated with OSA have been explained, at least in part, by 
increased sympathetic nervous activity related to numerous arousals during sleep 
secondary to obstructed breathing events (Somers & Javaheri, 2005; Dempsey, et aI., 
2010). Collectively, the literature does not agree whether OSA is a cause of 
cerebrovascular disease; however, several studies have found intima-media thickness of 
the carotid arteries, carotid plaques, and serum inflammatory markers to be increased in 
OSA patients (Baguet et aI., 2005; Minoguchi et aI., 2005). Drager et ai. (2005) found 
AHI to be an independent predictor of stroke, and the severity of OSA was associated 
with increased risk. 
Metabolic risks linked to OSA include the complex contribution of both sleep 
arousals/fragmentation and increased hypoxia/hypercapnia affecting adipocyte-derived 
inflammatory mediators, the sympathetic nervous system, and cortisol secretion at the 
hypothalamic-pituitary adrenal axis (Punjabi & Beamer, 2005). Thus, the causal pathway 
of metabolic dysfunction and OSA, as reported by Punjabi and Beamer, includes 
increases in sympathetic activity, along with changes in hypothalamic-pituitary-adrenal 
function, and a predisposition to a pro inflammatory state. Comprehensive reviews of 
studies involving OSA and metabolic disorders have shown consistent correlations 
between the severity of sleep-related hypoxemia, sleep duration, and glucose intolerance 
and insulin resistance, contributing to the risk ofT2DM (Punjabi, Ahmed, Polotsky, 
Beamer, & O'Donnell, 2003; Vgontas et aI., 2000). Likewise, a growing body of evidence 
has identified apnea-induced dysfunctionalleptin and leptin resistance, further affecting 
glucose intolerance, insulin resistance, T2DM, hypertension, and obesity (Coughlin, 
Mawdsley, Mugarza, & Calverley, 2004; Shimzu et aI., 2002). 
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Sleepiness poses one of the greatest risks to those with OSA, particularly as it 
relates to motor vehicle accidents. Sassani et al. (2004) conducted a meta-analysis of 
studies from 1980 to 2003, and when combined with National Safety Council data, 
findings revealed more than 800,000 drivers were involved in OSA-related motor vehicle 
accidents in 2000, costing $15.9 billion and 1400 lives. Drivers with OSA have been 
found have higher motor vehicle accident rates at 12% to 31 % versus 3% to 15% in 
drivers without OSA (Horstman, Hess, Bassetti, Gugger, & Mathis, 2000). Commercial 
long-haul drivers have been estimated to have a higher prevalence of OSA than the 
general population, 40% of whom have reported problems with alertness while driving 
and 20% of whom have reported dozing at the wheel (Hakkanen & Summala, 2000). 
Treatment 
To date, continuous positive airway pressure (CPAP) is considered the most 
uniformly effective treatment for OSA, and is the only intervention shown to consistently 
improve neurobehavioral and cardiovascular morbidities (Veasey et al. 2006). 
Unfortunately, as reported by Zozula & Rosen (2001), CPAP is often refused or poorly 
tolerated in as many as 25% to 50% of OSA patients. In many cases, conservative 
treatment for OSA is offered first line or combined with CPAP therapy. Conservative 
treatment focuses on lifestyle and behavioral modifications to improve overall sleep 
hygiene and sleep apnea. Such measures include maintaining routine sleep/wake activity 
with eight consecutive hours allocated to sleep, altering the sleep environment to control 
for comfort, noise and temperature, elevating the head of the bed, lateral or side-lying 
sleep position, relieving nasal rhinitis and congestion with intranasal corticosteriods, 
smoking cessation, reducing caffeine intake, avoiding alcohol, relaxants and sedative 
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medications, increasing physical activity, and avoiding naps (Phillips & Kryger). 
Unfortunately, according to Shneerson and Wright (2007) the value of these first line 
measures has not been established. 
Clinically, weight loss is often a primary recommendation in overweight and 
obese patients, and has been shown effective in reducing apneic events, particularly in 
cases where weight gain coincided with worsening of apnea and related symptoms 
(Phillips & Kryger, 2005). Despite effectiveness in alleviating OSA, weight loss for 
overweight and obese patients with moderate to severe OSA usually offers variable 
success, both short- and long-term (Shneerson & Wright, 2007). Exercise is often 
recommended as a weight loss strategy in addition to reduced calorie diets; although, 
little data are available as to the long-term success of such recommendations (Veasey et 
aI.,2006). An investigational study conducted by Winslow, Bowden, DiDonato, 
McCullough & Day (2010) showed promising results for pharmacologically treating 
OSA when combined with lifestyle modification. This study showed statistically 
significant weight loss and meaningful improvements in apnea, respiratory-related 
arousals, nighttime oxygen levels, subjective sleep quality, and blood pressure (Winslow, 
et aI.). 
Oral or dental appliances have been used with varying degrees of success in 
patients who snore, have mild sleep apnea, or are CP AP intolerant. These appliances are 
consistently preferred over CPAP, and have been shown to be more effective than 
surgical uvulopalatopharyngoplasty, both short- and long-term (Walker-Engstrom, 
Tegelberg, Wilhelmsson, & Ringqvist, 2002). Other surgical intervention for OSA has 
included tracheostomy, laser-assisted uvulopalatopharyngoplasty (LAUP), septoplasty, 
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oromaxillofacial surgery, and radiofrequency volumetric tissue reduction (somnoplasty) 
(Phillips & Kryger). Additionally, bariatric surgery has been applied in morbidly obese 
patients with OSA and has been successful in the treatment of OSA caused by obesity 
(Buchwald et aI., 2004). While surgical options are important treatment considerations 
for OSA patients, it is beyond the scope of reviewed literature for this study. Generally, 
as with most forms of OSA treatment, long-term treatment effect and evaluation is 
insufficient (Phillips & Kryger). Clearly, studies involving OSA and treatment follow-up 
would contribute to identifying better outcome measures for such an at-risk population. 
Continuous Positive Airway Pressure 
CP AP is considered the primary therapy and treatment of choice for moderate to 
severe OSA. CPAP was first described in 1981 (Sullivan et aI., 1981); although, clinical 
acceptance and application was not widespread until about 1985 (Grunstein, 2005). 
CP AP is a continuous positive flow of air pressure delivered via nasal mask, titrated and 
adjusted to a therapeutic level, and measured in centimeters of water pressure ranging 
from 5 to 15cm H20. The nasal mask is secured by headgear and is connected by a 6 foot 
flexible hose to a lightweight, portable CP AP machine. The CP AP mask is worn during 
sleep in order to alleviate snoring and apneic events. While CP AP does not increase 
upper airway muscle activity (Strohl & Redline, 1986), endoscopic and upper airway 
imaging has confirmed that CP AP does act as an upper airway pneumatic splint, 
increasing volume and airway area, reducing pharyngeal wall thickness and edema 
(Grunstein). The positive pressure is fixed and delivered continuously throughout 
inspiratory and expiratory cycles. Bilevel positive airway pressure therapy is an 
alternative to CPAP and is used in select cases to offer independent adjustment of 
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inspiratory and expiratory pressures, either to accommodate poor response to CP AP or to 
improve pressure tolerance and comfort. Ayas et ai. (2004) conducted a meta-analysis 
and found the use of auto-titrating positive pressure machines, versus traditional 
supervised PSG titrated and fixed continuous pressure machines (CPAP), has become 
more widely used, but studies have shown no improvement in tolerance or compliance 
even with modest decreases in pressure. Likewise, a Cochrane review of interventions to 
improve use of CP AP was conducted and revealed no clear advantage, or supportive data, 
to warrant replacing traditional, less expensive CP AP for more expensive auto-titrating 
units in the home (Haniffa, Lasserson, & Smith, 2004). 
Compliance 
Compliance with CP AP has been referred to in terms of acceptance, prescription, 
adherence, tolerance and usage (Grunstein, 2005). The most widely used term is 
compliance and will be the preferred term used in this study to indicate objective 
measurement of total time wearing CP AP while delivering the established and prescribed 
pressure. In recent years, CP AP machines have been manufactured and equipped with a 
sophisticated meter to measure actual compliance using a removable card and computer 
software to download compliance data (Grunstein). CPAP compliance studies have 
demonstrated wide ranges in findings. Some report 58% to 80% of patients refuse CPAP 
after initial trial, while others report a 50% CP AP purchase rate. Objective monitoring of 
CP AP compliance has revealed about 46% of OSA patients used CP AP 4 hours or more 
on at least 70% of the observed nights, with compliance at one month predictive of 
compliance at 3 months (Kribbs et aI., 1993; Weaver et aI., 1997). For lack of other data, 
this has been cited as the threshold, or minimally accepted value, for compliance. Those 
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who do not report symptomatic improvement or are unable to use CP AP at the minimal 
criteria are considered unresponsive or noncompliant with CPAP therapy. 
The major factors influencing compliance are most frequently associated with 
side effects, noise, aesthetics, bed partner intolerance, and inconvenience. Side effects of 
CPAP usually lead to poor compliance or discontinued use, and include rhinorrhea, nasal 
congestion, nasal/oropharyngeal dryness, epistaxis, skin abrasion/rash, conjunctivitis 
related to air leak, chest discomfort, sinus pressure, claustrophobia, and difficulty 
exhaling (Grunstein, 2005). There are multiple mask and interface options available to 
maximize comfort and fit for patients. Likewise, a ramp feature to allow gradual pressure 
increase is available on most CP AP machines, as is a built in humidifier to relieve 
dryness. Despite improvements in the size, shape, weight, and noise of CP AP machines, 
as well as mask interfaces, humidification and various accessories, compliance remains 
an issue. Hoy et aI. (1999) demonstrated that education and positive reinforcement by the 
healthcare provider improves compliance; however, the degree to which is necessary is 
not clear. Results of a meta-analysis confirmed that patients who have more severe 
symptoms and are sleepier at baseline have greater objective CPAP usage (Patel et aI., 
2003). 
Health benefits 
CPAP, when used, leads to less fragmented sleep, improves variable oxygen 
desaturation and changes and decreases cardiovascular workload and other forms of 
autonomic nervous system stimulation. CP AP has also been shown to improve leptin and 
ghrelin levels, central obesity, and insulin sensitivity (Babu, Herdegen, Fogelfeld, Shott, 
& Mazzone, 2005; Chin et aI., 1999; Harsch et aI., 2003; Harsch et aI., 2004). 
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Furthermore, findings suggest CP AP can reverse or reduce the risks associated with 
OSA, including mortality (Lavie, Lavie, & Herer, 2005; Marti et aI., 2002), hypertension 
(Becker et aI., 2003; Heitmann et aI., 2004; Pepperell et aI., 2002;), cardiovascular 
disease (Doherty, Kiely, Swan, & McNicholas, 2005; Kaneko et aI., 2003; Stoohs et aI., 
1993), cerebrovascular disease (Martinez-Garcia et aI., 2009), neuropsychologic and 
cognitive dysfunction (Bardwell, Ancoli-Israel, Berry, & Dimsdale, 2001; Borak et aI., 
1996; Derderian, Bridenbaugh, & Rajagopal, 1998), sleepiness (Yamamoto et aI., 2000), 
depression (Means et aI., 2003; Schwartz, Kohler, & Karatinos, 2005), impaired quality 
oflife (Jenkinson, Stradling, & Peterson, 1997; Sin, Mayer, Man, Ghahary, & Pawluk, 
2002), impotence (Karacan & Karatas, 1995), car crashes, and health care costs (Findley 
& Suratt, 2001; Sassani et aI., 2004). It has been estimated that treating all drivers who 
have OSA with CP AP would save 900 lives and yield a net savings of $11 million per 
year (Sassani et aI.). 
Although the benefits of nasal CPAP as an effective form of therapy for OSA has 
been well documented, treatment adherence and compliance remains problematic, despite 
known cardiovascular, metabolic, and quality of life benefits. While the data suggests 
favorable effects of CP AP, many questions and gaps remain, which include compliance, 
responsiveness to therapy, and long-term benefits (Caples, Gami, & Somers, 2005). 
According to Grunstein (2005) and Basner (2007), true CP AP compliance remains 
unknown, as most follow-up studies have biases related to selected patient populations 
and sampling. To address this need, the current and ongoing multi-center National Heart 
Lung and Blood Institute (NHLBI)-funded Apnea Positive Pressure Long-term Efficacy 
Study (APPLES) has been developed and designed to evaluate the long-term 
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effectiveness and benefits of CP AP in relation to improving neurocognitive function, 
mood, sleepiness, and quality of life (Kushida, 2007). Likewise, efforts from the Centers 
for Disease Control and Healthy People 2010 epidemiologic and surveillance studies may 
provide future insight into follow-up, long-term management and outcomes of CPAP 
therapy in patients with OSA. Additional research addressing responsiveness to therapy 
in terms of sleep and wake activity and CP AP compliance would offer contribution 
toward filling the gaps in the current body of knowledge and state of sleep science. 
Overweight and Obesity 
Obesity is one of the strongest identifiable risk factors for OSA. It has been 
estimated that 40% of all obese patients have OSA, and 70% of all patients with OSA are 
obese, with the risk of OSA in obese individuals ten times greater than that of the general 
population (V gontzas et al. 1994). Although not completely understood whether a cause 
or effect, cross-sectional studies have endorsed the relationship between obesity and OSA 
to be primarily associated with increased body mass index, central obesity, upper airway 
fat distribution, and large neck size (Tasali & Van Cauter, 2002; Tung, 2005; Young, 
Peppard, & Gottlieb, 2002). 
Overweight is considered weight in excess of the average for a given height; 
whereas, obesity is defined as an excess of body fat (Stunkard & Wadden, 1993). Obesity 
can be classified by level of fatness (total fat percentage of body weight), distribution of 
fat (location of stored fat), and body weight (Summerfield, 2001). The most commonly 
used measure to classify body weight is body mass index (BMI). BMI can be calculated 
using the formula: weight in kilograms divided by height in meters squared. The NHLBI 
established guidelines based on BMI for underweight «18.5), overweight (25-29.9), 
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class 1 obesity (30-34.9), class 2 obesity (35-39.9), and extreme obesity, class 3 (>40) 
(National Institutes of Health, 1998; National Institutes of Health, 2000). 
Obesity trends from the U.S. Centers for Disease Control and Prevention (CDC), 
Behavioral Risk Factor Surveillance System (2007) graphically demonstrate dramatic 
increases in the prevalence of obesity (BMI ~30) in the United States from 1985 to 2006 
(U.S. Department of Health and Human Services & Centers for Disease Control and 
Prevention, 2007). Of the states participating in the BRFSS in 1990, 10 had a prevalence 
of obesity less than 10% and no states had prevalence equal to or greater than 15% (U.S. 
Department of Health and Human Services & Centers for Disease Control and 
Prevention). By 1998, no state had prevalence less than 10%, seven states had a 
prevalence of obesity between 20 and 24%, and no state had prevalence equal to or 
greater than 25% (U.S. Department of Health and Human Services & Centers for Disease 
Control and Prevention). In 2006, only four states had a prevalence of obesity less than 
20%,22 states had a prevalence rate equal to or greater than 25%, and 2 states 
(Mississippi and West Virginia) had equal to or greater than 30% (U.S. Department of 
Health and Human Services & Centers for Disease Control and Prevention). These 
alarming figures have continued to rise, and even more recent data collected from 2009 
has shown only one state (Colorado) and the District of Columbia to have had a 
prevalence of obesity less than 20%. (U.S. Department of Health and Human Services, 
Centers for Disease Control and Prevention, 2011). According to National Health and 
Nutrition Examination survey (NHANES) data from 2003-2004, 66.3% of adults age 20 
and older are overweight or obese, and 32% are obese (National Center for Health 
Statistics, 2007). This same data reveals the prevalence of overweight in adolescents age 
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12-19 to be 17%, and children age 6-11 is 19% (National Center for Health Statistics). 
While the adult population is of interest to this study, overweight and obesity in children 
and adolescents have current, as well as future adult health implications. Overweight and 
obesity poses a major public impact in terms of health, healthcare costs, and quality of 
life. 
Specific factors implicated in the obesity epidemic include activity level and 
physical fitness, diet and nutritional intake, drug and alcohol use, and smoking 
(Summerfield, 2001). Health risk factors are associated with the level of overweight or 
obesity (higher BMI), age of onset and duration (younger and longer), location of fat 
storage (central or visceral), and race-ethnicity (African American and Hispanic) 
(National Institutes Of Health, 1998). Obesity is directly linked to cardiovascular disease 
and hypertension, (Wolk, Shamsuzzaman, & Somers, 2003; Wolk & Somers, 2006). In 
addition, dyslipidemia, T2DM, cancer, osteoarthritis, pregnancy complications and sleep 
apnea are associated with obesity (Caterson et aI, .2004; Flegal, Graubard, Williamson, & 
Gail, 2005; Summerfield, 2001; Wilson, D'Agostino, Sullivan, Parise, & Kannel, 2002). 
As previously discussed, findings have shown OSA to be not only a health risk factor 
associated with obesity, but an independent contributing factor to many of these same 
comorbidities (Caterson et aI, .2004; Dyken, Ali, Raman, & Eppen, 2007; Mullis et aI., 
2004). Furthermore, there is supportive evidence that metabolic and endocrine changes 
which promote obesity and diabetes may be a result of not only sleep disruption and 
arousal caused by OSA, but sleep loss and overall short sleep duration, as well (Chaput et 
aI. 2007; Hasler et aI., 2004; Spiegel, Leproult, & Van Cauter, 1999; Taheri, Lin, Austin, 
Young, & Mignot, 2004). 
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Obesity and obstructive sleep apnea 
Many studies have identified the relationship between obesity and OSA, with 
cross-sectional studies demonstrating increased body weight parallels the risk and 
severity of OSA (Young, Peppard, & Gottlieb, 2002). Prospective population-based 
studies have shown that a 10% weight gain resulted in a sixfold increase in developing 
OSA, while a 10% weight loss decreased the AHI by 26% (Peppard, Young, Palta, & 
Skatrud, 2000). As reported by Young et aI. (2002), the Wisconsin Sleep Cohort study, 
and the Cleveland Family Study revealed findings consistent with excess body weight 
and central obesity to be a significant predictor of OSA and increased AHI . Specifically, 
a BMI of>28 kg/m2 has been shown to increase the risk of OSA in both middle-aged 
men and women (Ancoli-Israel et aI., 2001). Although the prevalence of OS A associated 
with central obesity continues to increase with age (Kripke et aI., 1997), the link between 
obesity and OSA has been shown to decline for both genders after age 50 (Ancoli-Israel 
et aI.; Young et al; Young, Peppard, & Gottlieb). 
Weight loss approaches 
When considering weight loss approaches as treatment for obese and overweight 
OSA subjects, CP AP has been shown to decrease total body fat and central adiposity in 
only a few studies (Chin et aI., 1999; Loube, Loube, & Erman, 1997; Noseda, 
Kempenaers, Kerkhofs, Houben, & Linkowski, 1996). Interestingly, Peppard, Young, 
Palta, and Skatrud (2000) found newly diagnosed patients with OSA have a greater 
increase in weight the year prior to diagnosis, and patients who comply with CP AP 
tended to gain weight. Redenius, Murphy, O'Neill, AI-Hamwi, and Zallek (2007) also 
noted increased BMI in women after 1 year of CP AP, with no BMI change in controls. 
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Buchwald et ai. (2004) conducted a systematic review and meta-analysis ofbariatric 
surgery and indicated the impact of surgical weight loss, particularly gastric bypass, on 
OSA and AHI demonstrated favorable results. Grunstein, Stenlof, Hedner, Peltonen, 
Karason, and Sjostrom (2007) found improvement in the incidence of sleep apnea 
symptoms, diabetes, and hypertriglyceridemia two years following bariatric surgery. A 
study examining three non-surgical treatments for OSA (CPAP, oral appliance, and 
weight loss) found CPAP resulted in the most improvement in physiologic, symptomatic 
and quality oflife measures, followed by oral appliance (Lam et aI., 2007). In this study, 
weight loss demonstrated improved sleep parameters, but weight control was not 
uniformly effective (Lam et aI.). Kajaste, Brander, Telakivi, Patinen, and Mustajoki 
(2004) evaluated a cognitive-behavioral weight reduction program in the treatment of 
OSA, both with and without CP AP, and found weight loss was achieved with this 
program; however, adding CP AP did not offer any greater weight loss. Despite routine 
recommendations about the importance of weight loss in the treatment of OSA, there is 
very little documented clinical intervention. As reported by Peppard et aI., the Wisconsin 
Sleep Cohort Study found that further increases in weight and AHI would result if 
therapy directed toward overweight and obesity was neglected. 
Health consequences 
Obesity has been cited as responsible for between 300,000 and 400,000 deaths per 
year in the United States (Mokdad et aI., 2004; USDHHS, 2001; Allison et aI., 1999). 
Most ofthese deaths are attributable to coronary artery disease, hypertension, and T2DM 
(Mokdad et aI.; Allison et aI., 1999). It has been suggested that this number may be, at 
least in part, due to the prevalence of OSA in 30% of adults with a BMI > 30kg/m2 and 
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50% of adults with a BMI >40kg/m2 (Resta et aI., 2001). Both direct and indirect costs of 
obesity have been estimated at $117 billion per year related to medical and healthcare 
costs and associated comorbidities (USDHHS, 2001; Wolf & Colditz, 1998; Wolf, 1998). 
Given the present obesity trend and the strong relationship between obesity and 
OSA, health and healthcare costs can only be expected to rise exponentially without 
prioritizing public and individual healthy weight management and weight loss 
interventions at the national, state and local levels (See, Mensah, & Olopade, 2006). 
Programs and initiatives focusing on nutrition and physical activity have been developed 
with federal, state and local funding; however, sleep, as an important one-third of life and 
health, has been absent from these initiatives. Research addressing the OSA population, 
70% of whom are estimated to be overweight or obese, has relevance and importance to 
improving both individual and public health outcomes. 
Sleep Activity, Wake Activity, and Energy Expenditure 
The sum of activity during sleep and wake can be translated to total daily energy 
expenditure, with weight management a balance of energy intake and energy expenditure. 
Energy intake is measured by total kilocalories of dietary or nutritional food and 
beverage consumed, while energy expended is measured by level of activity, inclusive of 
both sleep and wake. A kilocalorie (kcal) is determined by the amount of heat required to 
raise the temperature of 1 kilogram of water 1 degree Celcius, which is measured using a 
bomb calorimeter. 
The 3 main components of energy expenditure include basal metabolic rate 
(BMR) and resting metabolic rate (RMR), dietary-induced thermogenesis (DIT), and 
physical activity or non-resting energy expenditure (Summerfield, 2001). BMR is usually 
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slightly lower than RMR, which can be more practically measured any time of the day 
and under less stringent conditions. Simplified, BMR is the total oxygen consumption of 
the active tissues in the body. Metabolic rate is the calorie expenditure required to 
support the body's cellular activity. As with measuring kcals, metabolic rates are 
determined by using direct calorimetry or indirect calorimetry (Summerfield). Direct 
calorimetry involves the use of a controlled chamber with walls lined with water to 
measure heat production and energy expenditure by temperature changes in water lining 
the walls of the chamber. While this method is more accurate, indirect calorimetry 
(spirometry) is often more practical, but still involves a face mask, hood or mouthpiece to 
measure inhaled oxygen and produced carbon dioxide using the respiratory quotient for 
calorie expenditure and estimated energy expenditure (Henning, Lofgren, & Sjostrom, 
1996). RMR is affected by many factors, including body size, thyroid hormone, 
nutritional status, gender, age, race, and heredity (Summerfield, 2001). Physical activity 
involves energy expenditure, but changes in RMR are debated by researchers. The type, 
intensity, and duration of physical activity, as well as age, gender and type and quantity 
of food ingested following the activity may all have some varied level of influence on 
RMR. Another factor related to energy expenditure is diet-induce thermogenesis (DIT), 
which is the production of heat by the body in response to eating, contributing to a rise in 
RMR. DIT is otherwise known as the thermic effect of food and involves the energy 
expended associated with dietary ingestion, digestion, absorption, and transport of 
nutrients, as well as increased sympathetic activity and heat production by brown adipose 
tissue (BAT) resulting from ingested calories. Lastly, non-resting energy expenditure or 
activities such as fidgeting, random muscle movements, activities of daily living, exercise 
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and other physical activities are included as the final component to measuring energy 
expenditure. 
A more practical measurement of energy expenditure for activity includes double-
labeled water method and heart rate monitoring (Ravussin & Rising, 1992; Summerfield). 
The first of which estimates carbon dioxide production from isotopes eliminated in the 
urine (Ravussin & Rising), with the latter using heart rate to estimate oxygen 
consumption and the amount of kcals expended. Metabolic equivalent tasks (MET) have 
been developed to estimate calorie cost of various physical activities and energy 
expenditure (Ainsworth et aI., 1993). Regardless of how measured, it is ultimately the 
difference between energy in and energy out that leads to weight gain, loss, and 
maintenance. 
Overweight and obese individuals have higher absolute RMRs, potentially 
dysfunctional BAT, and are less physically active than those with ideal body weight. As 
it relates to OSA, it has been shown that energy expenditure in OSA patients is greater 
during sleep than those without OSA (Bonnet, Berry, & Arandel, 1991; Stenlof, 
Grunstein, Hedner, & Sjostrom, 1996). This is speculated to be due to airway obstruction 
and hypoxemialhypercarbia resulting in increased arousals and disruption during sleep, 
along with increased sympathetic nervous system activity. Waking activity is less well 
studied, but also speculated to have the potential to be reduced in OSA patients due to 
daytime sleepiness and fatigue associated with OSA (Ancoli-Israel, 2005). Several 
studies have evaluated weight gain in OSA patients prior to and following diagnosis, and 
have evaluated weight loss interventions with and without various treatment modalities 
(CPAP, low calorie diets, behavioral and surgical intervention) (Buchwald et aI., 2004; 
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Kajaste et aI., 2004; Lam et aI., 2007; Peppard et aI., 2000; Redenius et aI., 2007; Young 
et aI., 2002) . These studies confirm the relationship between weight gain, overweight, 
and obesity and the development of OSA. They also endorse that weight loss, regardless 
of the intervention, decreases the severity of apneas and hypopneas and can improve 
OSA symptoms. Albeit limited, there is conflicting evidence regarding the ability of 
CP AP to reduce weight in OSA patients, with some evidence of weight gain. 
Two studies were found that addressed energy expenditure in OSA patients. A 
study by Ryan, Love, and Buckley (1995) identified a lack of evidence regarding the 
effects of sleep disorders on energy expenditure. Their research was interested in 
determining whether resting energy expenditure (REE) during wake and dietary 
thermogenesis were reduced in OSA patients. Energy expenditure was measured using 
indirect calorimetry in a metabolic cart and canopy system, further expressed in 
metabolic body size (Ryan et aI.). Patients with OSA had increased REE compared to 
matched-weight controls; however, once correction was made for lean body mass, both 
REE and dietary thermogenesis failed to show a difference between groups (Ryan et aI.). 
Measurements were repeated following CP AP therapy in the OSA patients, but again, did 
not reveal any differences in resting energy expenditure or dietary thermogenesis. 
Obesity in OSA patients was found to be lifestyle and diet-induced, and related to 
reduced waking energy expenditure, rather than hypothalamic mechanisms (Ryan et aI.). 
This would be consistent with speculation that OSA patients are more likely to gain 
weight prior to diagnoses and fail to lose weight following CP AP treatment, despite 
improvement in the hypothalamic-pituitary adrenal axis (Ancoli-Israel, 2005; Traviss, 
Barr, Fleming, & Ryan, 2002). 
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Stenlof, Gruenstein and Hedner (1996) examined 24-hour energy expenditure 
(EE) in 5 male patients with OSA and 6 control snoring sUbjects. Three months following 
CPAP treatment in the OSA patients, 24-hour EE was again conducted. In order to 
measure EE, patients were studied using indirect calorimetry in a controlled metabolic 
chamber equipped like a hotel room. Each patient was studied for a single 24-hour 
period, with those using CP AP studied an additional 24-hour period. OSA patients had 
higher sleep EE and 24-hour EE than the snorers. It was concluded that OSA increases 
sleep EE higher than quiet wakefulness, and treatment with CP AP decreases sleep EE by 
an average of 16% (Stenlof et al.). The researchers explained 3 possible mechanisms 
which could account for increased sleeping EE in OSA patients. These explanations 
included increased frequency of arousals during sleep due to apneic events, increased 
breathing efforts against upper airway occlusion, and increased sympathetic activity of 
the sympathetic nervous system (Stenlof et al.). There were no observed changes in 
daytime EE; although the authors indicated the study was limited due to the controlled 
environment and restriction of patient wake activity required for indirect calorimetry 
(Stenlof et al.). Stenlof et al. stated that ambulatory measures ofEE in OSA patients have 
yet to be performed, and findings of increased sleep EE in OSA patients have 
implications for energy and weight management. They further suggested that additional 
study of OSA patients should be conducted in an unrestricted and natural environment, 
which may offer utility in the development of weight loss strategies in this population 
(Stenlof et al.). Despite clinically relevant findings, both studies by Stenlof et al. and 
Ryan et al. were limited in the number of patients as well as the ability to study these 
patients in a 24-hour uncontrolled and natural setting. 
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Actigraphy 
When evaluating sleep and wake activity, actigraphs, actimeters, accelerometers, 
or activity monitors have been utilized as devices to record 24-hour movement or 
activity. For this study, actigraphy is the preferred term used to encompass all forms of 
this device in this review. In sleep, actigraphs have been most extensively used in the 
study of circadian rhythms, and were first used to differentiate sleep from wake in the 
early 1970's (Ancoli-Israel, 2005). With advances in technology, actigraphy has been 
applied to the evaluation of insomnia, circadian rhythm disorders, sleep-related breathing 
disorders, response to therapy, and sleep patterns in special populations (Morgenthaler et 
aI., 2007). In these instances, actigraphy has offered objective measurement of sleep 
duration and circadian patterns of sleep. Actigraphy, however, does not replace 
electroencephalogram-defined sleep or standard PSG; nor does it account for subjective 
measures of sleep experiences (Morgenthaler et al.). The device is simply meant to 
measure movement of a limb and is usually worn on the wrist or ankle. Despite the 
simplicity, actigraphy is highly sensitive and involves complex and sophisticated 
algorithms for estimating sleep and wake activity (Ancoli-Israel). The simple basis of this 
device is that it detects decreased movement or inactivity when sleeping and increased 
movement or activity while awake. The complex algorithms for scoring data have 
varying degrees of accuracy depending on the specific device, with some offering greater 
ability to distinguish wake, sleep, sleep onset, awakenings during sleep and total sleep 
time (Ancoli-Israel). A number of computer software programs are available with 
actigraphy devices and offer packages for editing and scoring of activity and sleep/wake 
data; however, most are used in combination with a manual activity or actigraph log to 
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aid in editing specific to time in bed, out of bed, unusual activity during the day or device 
removal (Ancoli-Israel). 
Actigraphy has been reported to be best at estimating total sleep time, but 
becomes less accurate with disturbed sleep (Elbaz, Roue, Lofaso, & Quera, 2002). 
Additionally, several studies have revealed actigraphy may underestimate wake (Bedner 
et ai. 2004; Lichenstein et aI., 2006), and a recent epidemiologic study also has reported 
the potential for overestimating sleep (Lauderdale et aI., 2006). Regardless, most studies 
have consistently shown actigraphy to be a valid assessment of sleep patterns with 
significant correlation to PSG in measuring total sleep time (Matsumoto et ai. 1998; 
Bedner et aI.; Vallieres & Morin, 2003). Advantages include its cost-effectiveness and 
ability to record sleep and wake activity in a natural environment, during both night and 
day for continuous 24 hour and extended periods oftime (Ancoli-Israel). 
In 2007, the American Academy of Sleep Medicine conducted an evidence-based 
review of the use of actigraphy in the clinical assessment and management of sleep and 
sleep disorders. In this review, actigraphy was used to describe a method of measuring 
increased wake time after sleep onset and "sleep pattern", defined as "the circadian 
pattern of sleep and wakefulness over multiple sleep cycles" (Morgenthaler et aI., 2007, 
p. 521). Recommendations for the use of actigraphy in clinical practice involved the 
following 3 areas: 1) actigraphy in the evaluation of sleep disorders; 2) actigraphy in 
assessing the response to therapy of sleep disorders; and 3) actigraphy in special 
populations and special situations (Morgenthaler et aI.). Practice parameters were 
developed based on evidence collected from 108 studies reviewed. Approximately 38 of 
these studies did not compare actigraphy to a reference standard, while 70 of the studies 
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compared actigraphy to a standard, such as PSG, phase markers, sleep logs/diaries or 
subjective estimates of sleep quality (Morgenthaler et aL). Studies have been conducted 
using actigraphy to determine total sleep time of healthy patients, patients with OSA, and 
infants, as compared to PSG, and found that there was a 90%,84% and 84% agreement 
in the two measures, respectively (Hedner et aL 2004). Studies have also used actigraphy 
in instances where PSG was not available to estimate total sleep time in OSA patients, in 
addition to using combined monitoring of respiratory events and actigraphy to assess the 
severity of OSA. Lastly, actigraphy has been shown to be useful in determining outcomes 
and treatment response for circadian rhythm disorders Get lag and shift work) and 
insomnia (Morgenthaler et aL). 
While both OSA and treatment response were addressed using actigraphy, there 
were only a few studies published that utilized actigraphy to evaluate response to CP AP 
treatment in OSA patients (Gadnoadoux, Nguyen, Rakotonanahary, Vidal, & Fleury, 
2004; Albert-Tulkens et aI., 1987). Gadnoadoux et aL were interested in correlating total 
sleep time (TST) in OSA patients using CPAP as measured by actigraphy, as compared 
to PSG, and found highly correlated sleep times with the exception of overestimations 
and underestimations in 3 out of26 patients. Albert-Tulkens et aL used wrist actigraphy 
to measure a movement and fragmentation index during sleep, and demonstrated higher 
indices of movement and fragmentation in patients with sleep apnea, with decreased 
indices following treatment. Neither ofthese studies (Gadnoadoux et al; Albert-Tulkens) 
addressed changes in total 24-hour sleep/wake activity after CPAP treatment. More 
recent publications by West, Kohler, Nicoll, & Stradling (2009) and Otake et aL (2010) 
studied the effect of CP AP on sleep/wake activity using actigraphy. West et aL studied 
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36 men with OSA and found there were no significant differences in activity levels one 
week before the initiation of CP AP as compared to one week after CP AP therapy. Otake 
et aI. confirmed agreement between PSG and actigraphy sleep/wake data, and further 
determined subjects treated after one month of CP AP had significantly less activity 
levels/movement than prior to CPAP. No additional research was found to support or 
negate the findings from these studies. In fact, more clinical and anecdotal evidence 
demonstrates otherwise. 
It has been concluded that additional research using actigraphy should be 
considered to further expand the value in clinical settings (Morgenthaler et aI., 2007; 
Ancoli-Israel, 2005; West et aI., 2009; Otake et aI., 2010). Because of advantages over 
subjective sleep diaries or logs, actigraphy has been cited as an important tool for use in 
follow-up studies to examine treatment efficacy and outcome (Ancoli-Israel). This is 
most relevant to this research study and purpose, as it relates to using actigraphy in 
assessing treatment outcome in sleep disorders; specifically, to evaluate the response of 
OSA patients to CPAP therapy, not in terms of determining respiratory events or isolating 
only sleep activity, but the assessment of total 24-hour sleep and wake activity combined 
with measures of CP AP compliance and energy expenditure. 
Because assessing total energy expenditure is important to this study purpose, an 
actigraphy device that measures sleep activity, wake activity, and calculated total energy 
expenditure would be of primary interest. Respironics® markets both the Actiwatch® 
and Actical® device, which offered utility as measurement tools for this study. While the 
Actiwatch® has been used extensively in sleep research to measure sleep and wake 
activity, the Actical® has not been used to measure activity and energy expenditure in 
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sleep, OSA, or CP AP patients. The intended use ofthe Actical®, as reported in 
premarket summary, is to serve as "a compact, lightweight, waist, wrist, or ankle worn 
activity monitor that may be used to assess human gross motor activity, caloric 
expenditure and estimates of energy expenditure based on motor activity in any instance 
where quantifiable analysis of physical motion is desirable" (Respironics, Inc®, 2006, 
pp. 1-2). To date, the Actical® has been used in a variety of metabolic, behavioral, 
activity, and physical exercise research, dating back to 1998, and has been validated in 
adult, child and adolescent populations (Mini Mitter®, 2003). The device uses an 
accelerometer to provide measurement of acceleration in activity counts and calculation 
of activity energy (calorie) expenditure. Sleep software programs are available with the 
Actiwatch®, and when combined with the Actical®, these are ideal devices to measure 
variables of sleep and wake activity and energy (calorie) expenditure for this study. 
Summary 
The literature identifies sleep to have restorative powers to improve wakefulness, 
increase attention and memory, and promote higher level mental and physical functioning 
and performance (Carskadon & Dement, 2005). Despite substantial sleep knowledge, 
there exists a pervasive failure to disseminate and translate existing knowledge and 
educate healthcare professionals and the public about sleep, sleep disorders and health 
(Walsh et al.; Institute of Medicine Committee on Sleep Medicine and Research Board on 
Health Sciences Policy, 2006). As a result, the numbers ofthose suffering with sleep 
disorders continues to grow, currently estimated at 50 to 70 million Americans, 18 
million of whom are estimated to have obstructive sleep apnea (U.S. Department of 
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Health And Human Services, National Institutes of Health, National Heart, Lung, and 
Blood Institute, & National Center on Sleep Disorders Research, 2003). 
OSA disrupts normal sleep architecture and physiology, resulting in many 
individual and public health risks (National Sleep Foundation, 2002; U.S. Department of 
Health And Human Services, National Institutes of Health, National Heart, Lung, and 
Blood Institute, & National Center on Sleep Disorders Research). Such risks include 
hypertension, neuropsychologic and cognitive dysfunction, impotence, sleepiness related 
motor vehicle crashes, cardiovascular disease, and stroke (Phillips & Kryger, 2005; 
Young, Peppard, & Gottlieb, 2002). Additional OSA risks include T2DM associated with 
glucose intolerance/insulin resistance and metabolic syndrome, and increased leptin 
levels associated with obesity (Punjabi & Beamer, 2005). Sleepiness, depression, 
decreased quality oflife, and increased health care costs (Kapur et aI., 1999; Won & 
Robert, 2007) have been linked to OSA as well. Clearly, OSA patients are an at-risk 
population. 
Although the benefits of nasal CPAP as an effective form of therapy for OSA has 
been well documented, treatment adherence and compliance remains problematic, despite 
known cardiovascular, metabolic and quality oflife benefits (Basner, 2007; Grunstein, 
2005; Phillips & Kryger, 2005). While the data suggests favorable effects ofCPAP, 
many questions and gaps remain including compliance, responsiveness to therapy and 
long-term benefits. Additional research addressing responsiveness to therapy in terms of 
sleep and wake activity and CP AP compliance would offer contribution toward filling the 
gaps in the current body of knowledge and state of sleep science. 
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As OSA relates to overweight and obesity, there is a direct link to cardiovascular 
disease, hypertension, dyslipidemia, T2DM, cancer, osteoarthritis, pregnancy 
complications, and sleep apnea (Won & Robert, 2007; Leinum, Dopp, & Morgan, 2009). 
Findings have shown OSA to not only be a health risk factor associated with obesity, but 
an independent contributing factor to many of these same comorbidities (Dyken, Ali, 
Raman, & Eppen, 2007; Leinum et al). Additionally, there is supportive evidence that 
metabolic and endocrine changes which promote obesity and diabetes may be a result of 
not only sleep disruption and arousal caused by OSA, but sleep loss and overall short 
sleep duration, as well (Spiegel, Leproult, & Van Cauter, 1999; Hayes, Xu, Babineau, 
Patel, 2011). Given the present obesity trend and the strong relationship between obesity 
and ~SA, health and healthcare costs can only be expected to rise exponentially without 
prioritizing public and individual healthy weight management and weight loss 
interventions. Research addressing the OSA population, 70% of whom are estimated to 
be obese, has such relevance and importance to both individual and public health. 
The Actiwatch® and Actical® are ideal devices, and in combination have the 
ability to measure sleep activity, wake activity and calculated total energy expenditure, 
respectively. To date, the Actical® has been used in a variety of metabolic, behavioral, 
activity and physical exercise research, and has been validated in adult, child and 
adolescent populations (Mini Mitter®, 2003). The device uses an accelerometer to 
measure both frequency and intensity of movement with activity counts and calculation 
of activity energy (calorie) expenditure. A software program is available for use with the 
Actiwatch® to download variables of sleep and wake activity. Likewise the Actical®, 
has a software program to download acquired data and determine energy ( calorie) 
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expenditure (Mini Mitter). Actigraphy, using the Actical® device, to evaluate EE in OSA 
patients has yet to be performed, but has implications for measuring energy expenditure 
and weight management in OSA patients. Combining the Actiwatch® and Actical® to 
study OSA patients in an unrestricted and natural environment, both prior to and 
following CPAP treatment, would contribute to measuring treatment efficacy, and 
provide data potentially useful to developing weight loss strategies in this population 
(Stenlof et al.). 
Overweight and obesity is a major factor in OSA, contributing not only to its 
pathogenesis, but complicating its management and contributing to related comorbidities. 
Clinically, addressing obesity treatment presents challenges to OSA patients and health 
care providers, with little evidence supporting CP AP as a significant weight loss measure. 
This study aims to contribute to the current state of sleep science by addressing an 
important knowledge gap in the treatment of overweight and obese OSA patients; 
specifically, to assess the effect of CP AP treatment on 24-hour total sleep activity, wake 
activity and energy expenditure as measured in a patient's routine and usual environment, 
while accounting for CP AP compliance. 
Current recommendations for research in OSA patients have highlighted the need 
for treatment outcome studies (Institute of Medicine Committee on Sleep Medicine and 
Research Board on Health Sciences Policy, 2006; U.S. Department of Health and Human 
Services, National Institutes of Health, National Heart, Lung, and Blood Institute, & 
National Center on Sleep Disorders Research, 2003). While there is evidence supporting 
favorable effects and improvement in sleepiness, quality oflife, and performance post-
CP AP therapy, the research does not address the effectiveness of CP AP in relation to 
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improving overall objective measures of continuous 24-hour total sleep/wake activity and 
energy expenditure. To address this knowledge gap, the present study proposed the use of 
actigraphy as a practical, convenient, and cost-effective method to measure 
responsiveness to CP AP therapy in terms of sleep/wake activity and energy expenditure. 
Furthermore, findings from this study may offer important clinical, social, and economic 
implications associated with evaluating CP AP effectiveness, as well as identifying factors 
critical to understanding and developing weight loss strategies for the overweight, obese, 





This study employed a prospective, observational, longitudinal, and repeated 
measures study design, in which data were collected from a single sample of overweight 
and obese adults diagnosed with OSA who required CPAP therapy. Primary study 
outcomes evaluated changes in 24-hour total sleep activity, wake activity, and energy 
expenditure over time as measured via actigraphy. Data were collected at three fixed time 
points: prior to CP AP treatment (time point 1 [Tl]), one week post-CP AP treatment 
(time point 2 [T2]), and 30 days post-CPAP treatment (time point 3 [T3]). At each time 
point, data were collected for 10 consecutive days and included 24-hour sleep activity, 
wake activity, and energy expenditure. Ten days was chosen to allow for the inclusion of 
both weekday and weekend data, providing a more comprehensive understanding of the 
effects of CP AP. Additionally, the pre-CP AP time point selection of a full week was 
based on the usual timeframe for clinical scheduling between consultation and diagnostic 
PSG. Post-CPAP time points were chosen to evaluate adjacent changes in the outcomes 
at the initial one-week pre-CPAP, as well as extended longitudinally to observe distant 
changes in the outcomes at the clinical standard of one month post-CPAP. In addition, 
prior research concerning compliance data has shown that CP AP use is often 
discontinued within the first one to two weeks after beginning treatment (Grunstein, 
2005); therefore, the one week post-CP AP was a critical time point for data collection 
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and provided the opportunity to collect data from those individuals who did not continue 
therapy through the 30-day time point. Furthermore, because CP AP compliance at one 
month has shown to be predictive of compliance at 3 months, additional time points were 
not included in the current study (Kribbs et aI., 1993; Weaver et aI., 1997). 
Sample and Setting 
The target population for this study was overweight and obese adults diagnosed 
with OSA. Participation was dependent upon a subject's eligibility, willingness to 
participate, and signed informed consent. Interested subjects were required to meet the 
following inclusion criteria: 1) male or female; 2) adults age 18 to 65; 3) able to speak, 
read and write the English language; 4) overweight or obese at baseline (BMI :::25); 5) 
initially present with signs and symptoms consistent with OSA and diagnostically 
confirmed with an AHI :::5 as determined by PSG; 6) require CP AP therapy (physician-
prescribed); and 7) maintain a regular sleep schedule, going to bed routinely between the 
hours of 9:00 pm and 1 :00 am and allowing 6 to 9 hours of sleep time. Likewise, 
potentially eligible subjects were excluded if they met any of the following exclusion 
criteria: 1) non-traditional work hours (night shift or swing shift work); 2) any known 
acute, unstable, or untreated medical conditions; and 3) pregnant or planning to become 
pregnant. 
Children and older adults have different sleep architecture and sleep requirements 
when compared to adults aged 18 to 65 (Carskadon & Dement, 2005); therefore, it has 
been recommended that children and adults older than 65 should be studied 
independently, and, as a result, were not recruited for the current study. This research did 
not pose a pregnancy risk; however, because both obesity and OSA may be affected 
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during pregnancy, pregnant women were excluded from study participation. Night shift 
and swing shift workers were not eligible for study participation due to the interrupted 
sleep/wake schedules involved in these types of shift work. Those with acute, unstable, or 
untreated medical conditions were not included in the study because these conditions 
could have affected their ability to undergo sleep study procedures and CP AP treatment. 
Minorities were not excluded from study participation. 
The sample population obtained for analysis represented a convenience sampling 
of patients evaluated at Sleep Medicine Specialists (SMS), a private physician practice in 
Louisville, Kentucky. Population demographics were evaluated prior to data collection 
and estimated to be 80% adult (ages 18 to 65), 75% male, 85% Caucasian, 75% privately 
(non-state funded) health insured, and less than 1 % uninsured. Approximately 85% of 
SMS patients are either self- or physician-referred for evaluation of OSA. On average, 
there are a total of 25 to 30 new sleep patients evaluated each week for OSA; therefore, 
subject recruitment and enrollment from this single site seemed feasible to adequately 
power this study. SMS is a practice of eight pulmonary physicians, all of whom are 
board certified in sleep medicine. In this setting, patients are initially seen for 
consultation in an outpatient physician office and subsequently scheduled for overnight 
testing in the sleep center. The sleep center is located adjacent to the physician offices. 
SMS maintains accreditation by the American Board of Sleep Medicine, and has a total 
of 10 diagnostic sleep rooms. The sleep rooms are appointed with standard or queen size 
beds, overhead lighting, bedside table, lamp, cable television, sink, and a chair. 
Restrooms with showers are located adjacent to sleep rooms. 
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Human Subjects Considerations 
The protocol and informed consent form (ICF) were approved by the University 
of Louisville Human Subjects Protection Program Office (HSPPO). Approval letters can 
be found in Appendix A. Subject recruitment material was not needed for subject 
enrollment. Eligible men and women, ages 18-65, as well as English-speaking minorities 
from the SMS practice, were recruited for this study. 
The ICF process was conducted by the investigator in a private exam room, and 
included a discussion and explanation of the study purpose and goal, study procedures, 
type of data collected, conflicts of interest, study funding or sponsorship, risks and 
benefits associated with the study, alternative procedures or treatment of OS A, 
compensation, study personnel contact information, and relevant patient confidentiality 
and health information protection and privacy issues (Polit & Beck, 2004). It was 
expected that study-related procedures would involve minimal risk to subjects. Emphasis 
was placed on the voluntary nature of study participation, and that the subject may 
withdraw at any time with no fear of their withdrawal from the study affecting their 
treatment. The subjects were informed that compensation would not be provided for 
study participation. Human subject protection, confidentiality, and health information 
privacy was also incorporated into the ICF and reviewed with study participants. 
Following a discussion, subjects were allowed adequate time to read the ICF and ask 
questions. All questions were answered by the investigator to the subject's satisfaction. 
No data collection or other study-related procedures were performed prior to the study 
participant signing ICF, and a signed ICF copy was provided to all subjects. 
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There were no conflicts of interest to be disclosed. Specifically, there was no 
compensation provided by the investigator to the referring SMS physician, nurse, clinical 
staff, or office practice. The investigator was not a clinical practitioner or an employee of 
SMS. The physicians, nurses, clinical staff, and investigator followed professional and 
ethical conduct and did not use coercive tactics for subject recruitment. Additionally, the 
SMS clinical staff and physician practice were not involved in data collection or analysis 
of the research. 
Measurement 
This study focused on changes in wake activity (time in minutes), sleep activity 
(time in minutes), and total energy (kilocalorie) expenditure over time, both prior and 
subsequent to CPAP therapy. The Actiwatch®-64 and Actical® devices were the 
instruments used to obtain these measurements. Philips-Respironics, Inc. provided 10 
Actiwatch® and Actical® monitoring devices, the ActiReader hardware, corresponding 
software programs, and instruction manuals for each monitoring system. As referenced 
in the literature review, most studies have consistently shown actigraphy to be a valid 
assessment of sleep patterns with significant correlation to PSG in measuring total sleep 
time (Matsumoto et aI., 1998; Hedner et aI.; Vallieres & Morin, 2003). Advantages of 
actigraphy include its' cost-effectiveness and ability to non-invasively and objectively 
record continuous physical movements during sleep and wake activity in a natural 
environment, over extended periods of time (Ancoli-Israel, 2005; Kushida et aI., 2001). 
Variables of interest to this study can be referenced in Table 1, with detailed discussion 
of each of these variables provided within separate sections labeled as outcome variables, 
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Table 1 
Variables and Measurement 
Variable 
Sleep activity (in minutes) 
Wake activity (in minutes) 











Body Mass Index 
Child-bearing Potential Status 
Medical History 
Apnea-Hypopnea Index 
CP AP Pressure 
CP AP Compliance 




Clinical Chart - Self-Report Questionnaire 
Clinical Chart - Self-Report Questionnaire 
Clinical Chart - Self-Report Questionnaire 
Clinical Chart - Self-Report Questionnaire 
Clinical Chart - Self-Report Questionnaire 
Clinical Chart - Self-Report Questionnaire 
Clinical Chart - Self-Report Questionnaire 




Clinical ChartlUrine Pregnancy Test 
Clinical Chart - Self-Report Questionnaire 
Clinical Chart - Polysomnographic Report 
Clinical Chart - CP AP Report 
EncorePro® SmartCard® 
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demographic variables, OSA and CP AP compliance variables, and height, weight, body 
mass index and pregnancy variables. 
Outcome variables 
Sleep, wake, and energy expenditure (EE) were the outcome variables of interest 
in this study and were measured using two wrist-worn actigraphy devices. The Actical®, 
as reported in premarket summary, is intended to serve as "a compact, lightweight, 
waist,wrist, or ankle worn activity monitor that may be used to assess human gross motor 
activity, caloric expenditure and estimates of energy expenditure based on motor activity 
in any instance where quantifiable analysis of physical motion is desirable" (Respironics, 
Inc®, 2006, pp. 1-5). This device uses an omni-directional piezoelectric accelerometer to 
provide measurement of physical motion. The degree of speed and motion produces 
voltage reading which is stored as an activity count. Activity counts have cut-point 
intensity values and corresponding algorithms for calculating activity energy expenditure 
(kcal·kg·min-1). The Actical® predicts EE and utilizes the Actical®, Version 2.10 
software to download data via the ActiReader® device (Respironics, 2007). An example 
of Actical® data can be found in Appendix B. 
To date, the Actical® has been used in a variety of metabolic, behavioral, activity 
and physical exercise research, and has been validated in adult, child, and adolescent 
populations (Mini Mitter®, 2003). Heil (2006) developed equations for predicting 
activity energy expenditure (AEE) in children and adults using the Actical® device. This 
laboratory-based study resulted in regression models with subsequent algorithms for 
predicting AEE based on physical activity intensity at three monitoring locations (hip, 
ankle and wrist). Heil concluded that these generalized prediction equations and 
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corresponding algorithms would provide useful assessment of time-based physical 
activity in groups of children and adults, but would likely never "accurately predict AEE 
for all activities in all people" (p. 76). Heil suggested monitors that allow for individual 
calibration could overcome this limitation; however, such a monitor has yet to be 
developed. Heil further reported physical activity and AEE measurement was sensitive to 
the body part that is responsible for the motion and that placement of the Actical® limits 
the precision of measurement when worn in a single location. In adults, both modeling 
algorithms accurately predicted light and moderate activities in all monitor locations but 
was most consistent for vigorous activity in the hip location. 
Crouter, Churilla & Bassett (2006) conducted a free-living study to examine the 
validity of predicted EE regression equations from three accelerometers (including the 
Actical®). These researchers compared the three accelerometers to indirect calorimetry 
across a range of sedentary to vigorous physical activities. Findings revealed that no 
single regression equation offered precise determination of the time spent in a specific 
activity intensity or an accurate prediction of corresponding EE. 
Rothney, Shaefer, Neumann, Choi and Chen (2008) also conducted a free-living 
study to validate EE predications from three different commercially available 
accelerometers, including the Actical®. These authors found less than 2% differences in 
moderate and vigorous physical activity prediction equations of the accelerometers as 
compared to room calorimeter measurements. Sedentary and light intensity activities 
tended to either over- or underpredict EE (Rothney et al.). This study offered similar 
conclusions as Heil (2006) and Crouter, et al. (2006), indicating the need for developing 
new regression equations to establish more accurate predictions of physical activity 
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intensity. Lastly, a study conducted by Feeney et al. (2007), addressed the validation of 
the Actical® in obese and non-obese middle-aged adults. This study found differences in 
currently established AEE and activity count cut-points when comparing the younger 
non-obese and middle-aged obese study participants. The results of this study suggested 
the need to establish specific age and body composition algorithms for measuring 
physical activity and EE with the Actical® accelerometer (Feeney, et al.). 
The Actiwatch® includes the Actiware®, Version 5.0 sleep software program to 
allow sleep and wake activity data to be downloaded via the ActiReader® and measured 
in time (Respironics, 2006). The complex algorithms for scoring and calculating data 
have been validated and score sleep and wake based on sampled epochs (15 second, 30 
second, 1 minute, or 2 minute) of activity counts. These activity counts are scored as 
either sleep or wake depending on whether the number of counts exceeds or falls below 
the established intensity thresholds set for sleep and wake. An example of the 
Actiwatch® data can be found in Appendix C. Like the Actical®, the Actiwatch® uses 
an accelerometer with a sensitivity ofless than .01 g-force to measure physical movement 
and produce an electrical current. The intensity of this electrical current is stored as an 
activity count and distinguishes wake, sleep, sleep onset, awakenings during sleep, and 
total sleep time (Ancoli-Israel, 2005). Kushida et al. (2001) compared actigraphic, 
polysomnographic, and subjective assessment of sleep parameters in sleep-disordered 
patients. Data for number of awakenings, total sleep time, and sleep efficiency were 
compared. Sensitivity, specificity and accuracy were calculated using the low- (high-
wake-sensitivity), medium- (medium-wake-sensitivity) and high- (low-wake-sensitivity) 
threshold algorithms from the Actiware® software program and compared to PSG and 
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questionnaire data. Findings from this study were comparable to an earlier study by 
Babin, Lee, Halko, Boudreau and George (1997) revealing higher sensitivity (0.98 -
actigraphic ability to detect sleep) for measuring sleep parameters in sleep disordered 
patients with the higher threshold algorithm at the cost oflower accuracy (0.80 -
actigraphic ability to detect both sleep and wake) and specificity (0.36 - actigraphic 
ability to detect wake). Overall, the accuracy of actigraphy in patients with sleep 
disorders has been reported to range between 0.78 and 0.85 (Blood, Sack, Percy & Pen, 
1997; Oakely, 1997; Sadeh, Hauri, Kripke & Lavie, 1995). 
While both the Actical® and Actiwatch have limitations in precision and accuracy 
associated with the individual nature of age, body composition, and free-living 
differences, each instrument offers validated measurements taken as a group. As such, the 
use of these instruments addresses a gap in the literature by combining measures of the 
Actiwatch® and Actical® device to measure the influence ofCPAP on sleep/wake 
activity and energy expenditure in the overweight and obese OSA study population. 
Demographic variables 
Demographic variables included gender, age, race, education level, work status 
and schedule, sleep schedule, marital status, height, weight, BMI, child-bearing potential 
status, and medical history. Medical history data relevant to OSA comorbid conditions 
included hypertension, myocardial infarction, heart failure, cerebrovascular accident, 
dyslipidemia, diabetes, and depression. A category to capture other medical conditions 
was included, as well. Some of these demographic variables were used to ensure 
appropriate subject selection based on established eligibility criteria. Otherwise, 
demographics were used to describe the sample population. Contact information (name, 
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date of birth, home address, and phone numbers) for each subject was collected in the 
event the investigator needed to reach the subject. This information (see Appendix D) 
was maintained separately from the subject's research data and stored in the co-
investigators secured, limited-access research office. 
GSA and CP AP compliance variables 
Polysomnography (PSG) was conducted as a routine clinical procedure for the 
diagnosis of OSA and CP AP titration. An AHI was obtained from the overnight PSG 
report on all subjects to determine if they met eligibility (AHt:5). For those eligible 
subjects requiring CP AP, a physician-prescribed CP AP pressure (centimeters of water 
pressure) was collected from the CP AP titration PSG study report (filed in the clinical 
chart). PSG acquisition, diagnostic scoring, and CPAP titration were conducted following 
standard clinical and technical procedures for an accredited sleep center. All clinical PSG 
diagnostic and CP AP titration studies were reviewed and interpreted by a SMS board 
certified sleep physician. A sample of OSA and CP AP titration in raw data PSG form can 
be referenced in Appendices E and F. Additionally, an example of both diagnostic and 
CP AP titration PSG reports can be found in Appendices G and H. 
CPAP compliance data was obtained from standard CP AP machines equipped 
with meters recording CP AP use on a removable card, which was downloaded by the co-
investigator into a computer software program to generate compliance (hours of usage) 
reports (see Appendix I). The CPAP machines prescribed from the SMS practice are 
manufactured by Philips-Respironics and incorporate the Encore® Pro SmartCard® 
technology to monitor and record the date, time and duration of CP AP use over a six 
month time period (Respironics, 2009). The Encore® Pro software allows the 
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development of a database for management of patient SmartCard® downloads, reports 
and compliance tracking. While not collected in the current study, the Encore® Pro 
system further records data on pressure trends, tidal volume, respiratory rate, triggered 
breathing percentage, minute ventilation, air leaks, and alarms (Respironics, 2009). 
Height, weight, body mass index and pregnancy variables 
Height and weight, with a calculated BMI were measured by the clinical staff and 
obtained from the subject's chart. These variables served as measures for determining 
study eligibility based on overweight or obese criteria, as well as for descriptive 
purposes. BMI was calculated by the SMS clinical staff, but was confirmed by the 
research co-investigator using the standard formula: weight in kilograms divided by 
height in meters squared. To meet study eligibility criteria, as required by the local 
HSPPO, a urine pregnancy test was conducted on all females of child-bearing potential 
(females were considered to be of child-bearing potential unless they reported 
spontaneous amenorrhea for at least 12 months or reported having had a hysterectomy 
and/or bilateral oophorectomy) to confirm negative urine human chorionic gonadotropin 
(HCG). 
Data Collection Procedures 
Subjects were recruited on a rolling basis from SMS over a 14 month time period, 
from November 2009 to January 2011. Clinical patients undergoing initial OSA 
evaluation at SMS were informed ofthe opportunity to be involved in a research study. 
All sleep nurses and physicians (clinical staft) at SMS were provided information about 
the research study and asked to identify potentially eligible subjects. A visit schedule of 
procedures can be referenced in Appendix J and data collection forms for all visits can be 
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found in Appendix K. All study procedures, with the exception of the urine pregnancy 
test and actigraphy (Actiwatch® and Actical®) training/instruction, monitoring, 
dispensing/return, and download, were routine standard of care for SMS. 
Visit 1.0 
Once a subject was deemed eligible and expressed an interest in participating, the 
investigator approached the patient to discuss the study purpose and procedures, privacy 
and protection of health information, and the risks and benefits of study participation. 
Upon the subject's verbal understanding and written signed/dated informed consent, the 
investigator proceeded with initial data collection from the subject's clinical chart, 
including initials, gender, age, race, education level, work status and schedule, sleep 
schedule, marital status, height, weight, BMI, child-bearing potential status, and medical 
history (hypertension, myocardial infarction, heart failure, cerebrovascular accident, 
dyslipidemia, diabetes, depression, and other). Contact information (home address and 
phone numbers) for each subject was also collected and maintained in a separate subject 
identification log. This information was used to communicate with the subjects and was 
maintained in the investigator's secured, limited-access research office. 
To meet the local HSPPO's requirements, a urine pregnancy test was collected on 
all females of child-bearing potential to determine pregnancy status during the first visit. 
Child-bearing information was obtained from all female subjects by the investigator to 
determine the need to collect urine pregnancy test. The subject's clinical chart was 
reviewed during Visit 1.0 to determine if the subject met study eligibility. Missing or 
unclear demographic information, relevant to the study, was clarified by the investigator 
during this visit. 
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The subject was then instructed on the use of the Actiwatch® and Actical® 
device and asked to wear both wrist devices 24 hours a day (without removing) for 10 
days prior to their scheduled diagnostic PSG (one week pre-CP AP data collection). Based 
on findings from an earlier unpublished pilot study, a 10 day actigraphy data collection 
period was chosen in order to collect a full week (seven days) of continuous 24 hour data 
(including five weekdays, Monday through Friday, and two weekend days, Saturday and 
Sunday) (McCullough, 2008). This pilot study collected actigraphy data for seven days 
but yielded only five days of evaluable data with the starting day (Day 1) and ending day 
(Day 7) days having partial data (less than 24 hours). 
Visit 2.0 and 2.1 
At Visit 2.0, subjects returned for overnight PSG, which was either a diagnostic 
PSG with a second CP AP treatment/titration PSG, or a single split diagnostic PSG and 
CPAP treatment/titration PSG (split night study). Split night studies are determined by 
sleep time and OSA severity per health insurance/medical coverage plans. Whether a 
subject underwent a single split diagnostic/treatment night (Visit 2.0) or two nights for 
diagnosis and treatment (Visit 2.1) could be considered a potential confounding factor in 
the final data analyses. Those study participants who required 2 nights for diagnosis and 
treatment experienced a lapse of time between the diagnostic PSG (Visit 2) and the CP AP 
treatment/titration PSG (Visit 2.1). This lapse of time was one to two weeks, depending 
on the clinical schedule. The AHI (2:5) and prescribed CP AP pressure were collected 
from the PSG report filed in the clinical chart. All PSG acquisition and scoring, as well as 
CP AP titration, were conducted by a trained SMS PSG technologist and interpreted by a 
SMS board certified sleep physician. 
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During Visit 2.0, actigraphy data download from both the Actical® and 
Actiwatch® was conducted. All eligible subjects were scheduled by the SMS office staff 
to return for a routine CP AP set-up office visit. Additional data collected at this visit 
included any reported adverse events related to study participation and/or procedures. 
Visit 3.0 
Subjects returned for a routinely scheduled clinical office visit at SMS for CP AP 
set-up. The durable medical equipment company (DME) provided the Philips-
Respironics CP AP equipment, compliance SmartCard®, and necessary training and 
instruction on home use of the equipment, as usual and customary. During Visit 3.0, the 
investigator saw the subject and provided instruction and training on the use of the 
Actical® and Actiwatch® devices. The actigraphy devices were dispensed to the subject 
and they were asked to again wear both wrist devices 24 hours a day (without removing) 
for approximately forty days starting on the first day of CP AP therapy at home (in order 
to obtain both the one week and one month post-CP AP time points for data collection). 
Additional data collected at this visit included any reported adverse events related to 
study participation and/or procedures. 
Phone Contact 
Subjects were contacted by the investigator (by phone) approximately 10 to 14 
days following the first day of CP AP use at home. This phone contact served to assess 
the subject's use of the Actical® and Actiwatch® devices and CPAP therapy. Additional 
data collected at this visit also included any reported adverse events related to study 
participation and/or procedures. 
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Visit 4.0 
Subjects returned for a regularly scheduled clinical office visit at SMS after 
approximately one month of CP AP treatment home. During Visit 4.0, the investigator 
saw the subject and performed a CP AP compliance data download and an actigraphy data 
download from both the Actical® and Actiwatch® devices. Additional data collected at 
this visit included any reported adverse events related to study participation and/or 
procedures. This visit concluded study participation for the subject. 
With the exception of PSG acquisition and scoring and CP AP titration, all data 
collection and procedures involving the Actiwatch® and Actical® devices and related 
subject visits were conducted by the co-investigator. Total subject duration in the study 
was dependent on clinical diagnostic and treatment scheduling with an expected duration 
of about two months. 
The initial office visit, PSG, CP AP titration, CP AP machine/supplies/compliance 
card, and any associated education or instruction is considered standard care for OSA 
patients and was subject to usual healthcare billing procedures by SMS and the DME 
company. The training and use of the Actiwatch® and Actical® device did not fall under 
usual care and was considered a study-related procedure. Subjects were not compensated 
for any standard of care procedures or study-related procedures. 
Data Management Procedures 
Unique identifiers were assigned to each subject to maintain anonymity (except to 
those directly involved in the research). Each subject had a 3 digit number consecutively 
assigned beginning with 001. All study participant information was stored in the 
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investigator's secured, limited-access research office. Furthermore, all research data were 
collected, maintained, and entered for statistical analysis by the investigator. 
Statistical Analysis 
Descriptive analysis 
Data analyses were performed using SPSS version 17.0 (SPSS, 2008). Study 
demographics were obtained for the entire sample, and descriptive statistics were 
calculated. Differences in demographic variables between those subjects who completed 
all study time points and those who did not complete all study time points were tested 
using t-test for continuous variables and Chi-square tests for categorical variables. The 
analytic sample was then dichotomized into CP AP compliant (~ 4 hours/night on 70% of 
the observed nights) and CP AP noncompliant « 4 hours/night on 70% of the observed 
nights) to test for differences between these two groups. These differences were tested 
using Chi-square techniques for all categorical data and t-tests for all continuous 
variables, utilizing an alpha of 0.05. 
Inferential analysis 
Three separate two-factor repeated measures analysis of variance (ANOVA) 
models were developed to detect overall group differences between pre-CP AP (T 1), 1 
week post-CPAP (T2), and 30 days post-CPAP (T3) on 24-hour sleep, wake, and energy 
expenditure. Repeated measures ANOVA allowed for group comparisons of the three 
study variables at different points over time (Munro, 2005), specifically testing for main 
effects for group (CP AP compliant versus CP AP non-compliant) and time. Utilizing 
repeated measures offered the ability to decrease the error term, while requiring fewer 
subjects to increase the power of the analysis (Munro). Although this study did not 
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involve a random sample, the research met other ANOV A assumptions, which included 
continuous dependent variable observed across mutually exclusive groups (the dependent 
variable observations are independent) and equal variances (homogeneity) across the 
groups on the dependent variable (observations on the dependent variable follow a 
normal distribution in each group) (Stevens, 2002). 
While repeated measures ANOV A is an omnibus test, post-hoc comparisons are 
needed if an effect is seen for variables with more than two levels (e.g., three time 
points). As such, paired (-tests techniques were performed to test the sub-hypotheses for 
differences between two time points. The analyses conducted allowed for exploration of 
the following hypothesized outcomes (hypothesis I [HI], hypothesis 2 [H2], hypothesis 3 
[H3]): 
HI) Subjects will have a significant decrease in total 24-hour sleep activity over time 
as a result of using CP AP (measured by the Actiwatch®) 
Hla. compared to pre-CPAP, there will be a significant decrease in 24-hour 
total sleep activity (time in minutes) 7 days post-CPAP 
Hib. compared to pre-CPAP, there will be a significant decrease in 24-hour 
total sleep activity (time in minutes) 30 days post-CPAP 
H2) Subjects will have a significant increase in total 24-hour wake activity over time 
as a result of using CP AP (measured by the Actiwatch®) 
H2a. compared to pre-CP AP, there will be a significant increase in 24-hour 
total wake activity (time in minutes) 7 days post-CPAP 
H2b. compared to pre-CP AP, there will be a significant increase in 24-hour 
total wake activity (time in minutes) 30 days post-CPAP 
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H3) Subjects will have a significant increase in energy expenditure over time as a 
result of using CPAP therapy (measured by the Actical®) 
H3a. compared to pre-CP AP, there will be a significant increase in 24-hour 
total energy (kilocalorie) expenditure 7 days post-CPAP 
H3b. compared to pre-CPAP, there will be a significant increase in 24-hour 
total energy (kilocalorie) expenditure 30 days post-CPAP 
The first hypothesis 1 (H 1) examined the effect CP AP had on sleep activity; H2 
examined the effect CP AP had on wake activity; and H3 explored the effect CP AP had 
on energy expenditure. For each outcome, separate repeated measures ANOVA models 
were developed. 
Sample size calculation 
An a priori statistical power analysis was conducted using the G*power 3.0 
program to determine the number of subjects required to adequately power the repeated 
measures ANOVA analysis and study design (Faul, Erdfelder, Lang, & Buchner, 2007). 
The program's field options were populated to include a single group, within factor 
ANOVA with 3 time points. Because the magnitude of the relationship (treatment effect) 
of CP AP treatment on sleep/wake activity and energy expenditure has not been well 
established in prior research, the estimated effect size used for the sample size calculation 
was set at a 0.25, defined as a moderate effect size using Cohen's d (Cohen, 1988). The 
effect size chosen is also consistent with effect sizes routinely reported in the social 
sciences and nursing research (Polit & Beck, 2008; Cohen). Additionally, correlation 
occurs when repeated measures are obtained from the same individual over time, with 
adjacent time points being more correlated than distant time points. Therefore, the 
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correlation values were set at 0.5 for adjacent time points (Tl, T2 and T2, T3) and 0.25 
for the distant time points (Tl, T3). The desired power was set at 0.80 with a 0.05 test 
significance level. Using these parameters, a sample size of 34 was needed to achieve an 
actual power of 0.81. That is, to adequately power the current study, 34 subjects were 
needed to complete all three data collection time points. 
In order to obtain a final sample size of 34, an attrition rate had to be anticipated. 
It has been reported that 58% to 80% of patients either initially refuse or do not continue 
CPAP treatment following a trial (Basner, 2007; Grunstein, 2005); however, objective 
monitoring of CP AP compliance has more accurately revealed about 46% of OSA 
patients used CP AP 4 hours or more on at least 70% of the observed nights, with 
compliance at one month predictive of compliance at 3 months (Kribbs et aI., 1993; 
Weaver et aI., 1997). Using a 54% attrition rate to conservatively estimate total sample 
size, it was projected that 74 subjects needed to be recruited and enrolled in order to 
obtain n=34 at T3. The observed attrition rate was slightly less than 54%, requiring only 
69 enrolled subjects (51 % attrition). Study recruitment ceased once 34 individuals 
completed all three data collection time points. All remaining enrolled subjects were 
allowed to continue through all study protocol procedures, with a total of 35 subjects 
completing all three time points. The enrollment period for this study was slightly over 
14 months. The first subject was consented November 17,2009, and the final subject 




A total of 69 subjects were initially consented and enrolled into the current study. 
Of the 69 consented, six did not complete a diagnostic sleep study (PSG) and six did not 
demonstrate an AHI 2: 5. The remaining 57 subjects qualified for CPAP treatment; 
however, seven did not elect this form of therapy, leaving 50 eligible study participants 
completing pre-CPAP time point 1 (n=50). Twelve (24%) of these 50 subjects did not 
complete the one week post-CPAP time point (n=38) and 3 did not complete the one 
month post-CPAP time point (n=35). Figure 2 (Study Flow Diagram) illustrates the 
study enrollment and participation process. 
Descriptive Statistics 
Eligible sample 
Demographic variables for the eligible subjects (n=50) were obtained and can be 
referenced in Tables 2 and 3. The mean age for the eligible sample was 49.3 years and 
52% were male. The mean body mass index (BMI) was 37.5, the average apnea-
hypopnea index was 26.9, and the mean CPAP pressure was 9.96 cm H20. The sample 
was 82% Caucasian, with African-American comprising the remaining 18%. More than 
one-third (38%) ofthe sample reported a high school education level, with 28.0% 
reporting a college graduate level (16 years of education). Only 2% had less than 12 
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Figure 2. Study Flow Diagram. 





o Not meeting inclusion criteria (n=12) 
• 6 did not complete diagnostic PSG 
• 6 had an AHI <5 
o Declined CPAP treatment (n=7) 
~ 
I Eligible Participants (n=50) I 
~ 
l Data Collection Time Points/Analvses J 
~ 
Time Point 1 (TI) - Pre-CPAP (n=50) 
~ 
Time Point 2 (TI) - 7days Post-CPAP (n=38) 
• Did not wear Actiwatch®IActical® (n=7) 
• Discontinued CPAP (n=5) 
~ 
Time Point 3 (T3) - 30 days Post-CPAP (n=35) 
• Incomplete CP API Actiwatch®1 Actical® data (n=3) 
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Table 2 
Descriptive Data o/Eligible Subjects - Continuous Variables 
Variable Minimum Maximum Mean (SD) 
Eligible Subjects (n=50) 
Age 28 65 49.3 (10.47) 
BMI 27.3 60.9 37.5 (7.41) 
Am 5.3 135.3 26.9 (24.49) 
CP AP Pressure 6.0 16.0 9.9 (2.91) 
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years of education and 8% reported post-graduate education. The majority were married 
(62%), with 22% single, 10% divorced, 2% widowed, and 4% separated. Work status 
revealed 58% full-time workers, 14% part-time workers, 12% unemployed, 10% 
disabled, and 6% retired. Hypertension was the most frequently reported medical 
condition by 21 subjects, followed by 11 reporting dyslipidemia. A list of additional 
medical conditions reported by the sample of eligible subjects has been summarized in 
Table 4. There were seven subjects who had reported no medical history. 
Completed and early-term sample comparisons 
The sample (n=50) was stratified into completed subjects (n=35) and early-term 
subjects (n=15). Completed subjects (n=35) were those participants who completed all 
three time points (Tl, T2, and T3) for the study. Early-term subjects (n=15) were those 
who completed only the first two time points (Tl and T2). To determine if demographic 
differences existed between these groups, t-tests were performed on all continuous 
variables and Chi-square techniques on all categorical data, with the significance test 
level at 0.05 (see Table 5). 
Of the eligible study participants (n=50), the completed subjects were 
significantly older (p=.026) than the early-term subjects (51.4 versus 44.3 years). BMI 
was also statistically different (p=.013), with those completing the study having a lower 
mean BMI (35.8 versus 41.3). The completed subjects group included more males 
(57.1 %) than the early term subjects (40%), but was not found to be significantly 
different. Both groups were predominately Caucasian. The average AHI (22.9) and 
CP AP pressure (9.7) was lower for those who completed compared to those who did not 
(36.1 and 10.4, respectively), but was not significantly different. The majority of each of 
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Demographic Data Comparison o/Completed and Early-Term Subjects 
Variable Completed Subjects Early-Term Subjects p-value 
n=35 (%) n=15 (%) 
Age 51.4 (10.62) 44.3 (8.45) .026* 
Gender 
Male 20 (57.1%) 6 (40.0%) .266 
Ethnicity 
Caucasian 31 (88.6%) 10 (66.7%) .065 
Education 
<12 years 1 (2.9%) 0(0.0%) .508 
High School 15 (42.9%) 4 (26.7%) .279 
TechIV ocational 1 (2.9%) 4 (26.7%) .010* 
College Grad (14yrs) 9 (25.7%) 5 (33.3%) .582 
College Grad (16yrs) 7 (20.0%) 0(0.0%) .062 
College Grad (18yrs) 2 (5.6%) 2 (13.3%) .363 
Marital Status 
Single 7 (20.0%) 4 (26.7%) .602 
Married 22 (62.9%) 9 (60.0%) .849 
Divorced 3 (8.6%) 2 (13.3%) .607 
Widowed 1 (2.9%) 0(0.0%) .508 
Separated 2 (5.7%) 0(0.0%) .345 
Work Status 
Unemployed 4 (11.4%) 2 (13.3%) .849 
Part-time 5 (14.3%) 2 (13.3%) .929 
Full-time 21 (60.0%) 8 (53.3%) .662 
Disabled 2 (5.7%) 3 (20.0%) .123 
Retired 3 (8.6%) 0(0.0%) .242 
BMI 35.8 (7.27) 41.3 (6.38) .013 * 
Am 22.9 (18.99) 36.1 (33.05) .080 
CP AP Pressure 9.7 (2.75) 10.4 (3.31) .489 
*Indicates statistical significance at the .05 level. 
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the samples was married, having at least a high school education, and working full-time. 
While overall education status was similar for both groups, there was a statistically 
significant difference detected in TechnicalNocational education level (p=.010), with 
those not completing the study having a higher percentage of technical/vocational 
education (26.7%) as compared to those completing the study (2.9%). 
Compliant and noncompliant sample comparisons 
The sample of completed subjects (n=35) was stratified into CPAP compliant (~ 4 
hours/night on 70% of the observed nights) and CPAP noncompliant « 4 hours/night on 
70% of the observed nights) groups for analysis. Table 6 outlines CPAP compliance for 
the completed study participants. CPAP compliance for those completing the study 
(n=35) was, on average, 313.6 minutes (5.2 hours) per night. The compliant group 
(n=21) at T2 (7 days post-CPAP) had a minimum, maximum, and mean use of219.7 
minutes (3.7 hours), 594.9 minutes (9.9 hours), and 396.3 minutes (6.6 hours) per night, 
respectively. Minimum CPAP use per night at T2 for the noncompliant group (n=14) 
was 38.0 minutes, with a maximum usage of 521.0 minutes (8. 7 hours), and an average 
use of273.6 minutes (4.6 hours). Compliance dropped for the noncompliant group at T3, 
with the minimum number of minutes used per night 0.0, a maximum use of267.6 (4.5 
hours), and average use of 180.6 (3.0 hours). Compliance improved for the compliant 
group at T3, with minimum, maximum, and mean minutes of271.0 (4.5 hours), 638.9 
(10.6 hours), and 402.3 (6.7 hours). As noted in Table 7, when compliant subjects (n=21) 
were compared to the noncompliant (n=14) completed subjects, there were no significant 
differences found on any of the demographic variables tested. 
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Table 6 
CPAP Compliance for Completed Subjects 
CP AP Compliance 
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Demographic Data Comparison ojCPAP Compliant and Noncompliant Subjects 
Variable CP AP Compliant CP AP Noncompliant p-value 
Subjects (n=21) Subjects (n=14) 
Age 48.8(11.59) 55.4(7.74) .071 
Gender 
Male 12 (57.1 %) 8 (57.1%) 1.000 
Ethnicity 
Caucasian 19 (90.5%) 12 (85.7%) .664 
Education 
<12 years 0(0.0%) 1 (7.1 %) .214 
High School 9 (42.9%) 6 (42.9%) 1.000 
TechIV ocational 0(0.0%) 1 (7.1%) .214 
College Grad (14yrs) 5 (23.8%) 4 (28.6%) .752 
College Grad (16yrs) 5 (23.8%) 2 (14.3%) .490 
College Grad (l8yrs) 2 (9.5%) 0(0.0%) .234 
Marital Status 
Single 4 (19.0%) 3 (21.4%) .863 
Married 12 (57.1 %) 10 (71.4%) .392 
Divorced 3 (14.3%) 0(0.0%) .139 
Widowed 1 (4.8%) 0(0.0%) .407 
Separated 1 (4.8%) 1 (7.2%) .766 
Work Status 
Unemployed 1 (4.8%) 3 (21.4%) .129 
Part-time 3 (14.3%) 2 (14.3%) 1.000 
Full-time 15 (71.4%) 6 (42.9%) .091 
Disabled 0(0.0%) 2 (14.3%) .075 
Retired 2 (9.5%) 1 (7.1 %) .805 
BMI 34.9(5.99) 37.0(8.95) .415 
Am 22.2(19.49) 24.0(18.87) .782 
CP AP Pressure 10.1(2.79) 9.2(2.67) .334 
*Indicates statistical significance at the .05 level. 
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Repeated Measures Analysis of Variance 
Three separate repeated measures ANOVA tests (Table 8) were performed for 
each of the outcome variables. Measures of sleep activity, wake activity, and energy 
expenditure were entered into the ANOVA models to test for group effects (mean 
differences in each outcome variable between CP AP compliant and noncompliant 
groups), a time effect (mean differences in each outcome variable between time points) 
at baseline [TI], 7 days post-CPAP [T2], and 30 days post-CPAP [T3]), and a group x 
time interaction effect (mean differences among the compliant or noncompliant groups at 
any ofthe time points). As shown in Table 8, all three models demonstrated a significant 
group effect with all p-values <0.001. Both sleep (p=.OI4) and wake (p=.024) 
demonstrated significant time effects; however, neither outcome had significant 
interaction effects (p=.838 and p=.997, respectively). Energy expenditure was not found 
to have a significant time effect (p=.260) or interaction effect (p=.878). 
Figures 3, 4, and 5 graphically depict sleep activity (minutes), wake activity 
(minutes), and energy expenditure (kilocalories) over time, stratified by compliance, 
respectively. In Figure 3, sleep shows an increased sleep activity time in both compliant 
and noncompliant groups from TI-T2, and a continued increase from TI to T3. Both 
groups had decreased wake activity time from TI-T2 with a continued decline from TI-
T3. While not statistically significant, Figure 5 shows a decrease in energy expenditure 
for both groups from TI-T2, with both the compliant and noncompliant groups showing a 
continued decrease from TI-T3. Although this research was interested in only measuring 
pre-CPAP (TI) to one week post-CPAP (T2) and one month post-CPAP (T3), the results 
for EE from repeated measures ANOVA (see Figure 5) showed an increase in EE from 
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Table 8 
Repeated Measures ANOVA of Sleep Activity, Wake Activity, and Energy Expenditure 
Over Time Stratified by Group 
Outcome Predictors F p-value 
Sleep Activity Compliance 501.6 <.001 *** 
Time 6.801 .014 *** 
Compliance*Time 0.42 .838 
Wake Activity Compliance 1214.5 <.001 *** 
Time 5.620 .024 *** 
Compliance*Time 0.000 .997 
Energy Expenditure Compliance 647.3 <.001 *** 
Time 1.312 .260 
Compliance*Time 0.024 .878 
***Indicates statistical significance at the .05 level. 
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T2 to T3 in the CP AP noncompliant group. 
Paired t-tests 
Paired t-tests (Tables 9 and 10) were performed to provide more detailed 
information and allowed examination of mean differences in each variable from Tl to T2 
(n=38) and Tl to T3 (n=35) for the entire group, and both compliant and noncompliant 
groups. Sleep time increased from pre-CPAP (baseline) to 7 days post-CPAP (one week) 
and 30 days post-CP AP (one month) regardless of compliance status. Statistically 
significant differences in sleep were demonstrated in the total group (p=.004) and 
compliant group (p=.012) from TI-T2, and the total group (p=.010) and noncompliant 
group (p=.007) from TI-T3. Wake time showed a decrease across the same time points 
for all groups, with significant decreases for the total group (p=.009) and compliant group 
(p=.031) from TI-T2, and the total group (p=.019) and noncompliant group (p=.008) 
from T 1-T3. Energy expenditure revealed decreases in all groups, across both time 
points, although not significant. While an increase in energy expenditure from T2 to T3 
can be seen in Figure 5 for the noncompliant group, additional analyses (Table 11) found 
this change was not statistically significant (p=.315). 
Consistent with repeated measures ANOVA testing, there were total group 
differences noted for sleep activity and wake activity from TI-T2 and TI-T3~ however, 
energy expenditure did not reveal any significant differences for the total group between 
any time points. Interestingly, mean differences in sleep and wake were significant in the 
compliant group from TI-T2, but were not from TI-T3. Conversely, significant 
differences in sleep and wake were observed in the noncompliant group from TI-T3, but 
not from Tl-T2. Likewise, repeated measures ANOV A demonstrated significant group 
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Table 9 
Paired t-tests: Sleep Activity, Wake Activity, and Energy Expenditure Stratified by Group 
at Adjacent Time Points 1 to 2 
Outcome Variable 
Sleep Activity 


















































Paired t-tests: Sleep Activity, Wake Activity, and Energy Expenditure Stratified by Group 
at Distant Time Points 1 to 3 
Outcome Variable 
Sleep Activity 












































4189.6(1042.0) -125.9(611.3) .231 
4214.9(1014.3) -139.2(704.2) .376 
4151.6(1119.9) -105.9(462.4) .407 
*Indicates statistical significance at the .05 level. 
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Table 11 
Paired t-tests: Sleep Activity, Wake Activity, and Energy Expenditure Stratified by Group 
at Time Points 2 to 3 
Outcome Variable 
Sleep Activity 

















































effect in energy expenditure, but paired t-tests failed to reveal statistically significant 
mean differences for the total group, compliant group, or noncompliant group. While 
these findings seem counterintuitive, they are consistent with Simpson's Paradox, in 
which a correlation or trend is observed when groups are stratified to test for marginal 
effects, but becomes non-significant when groups are combined (Cohen, 1988). This is 
often a result of confounding factors and caution should be exercised in making causal 
inferences about the data (Cohen), specifically the effect of CPAP on sleep activity, wake 





The purpose of this research was to examine the influence of CP AP on sleep 
activity, wake activity, and energy expenditure. Overweight (BMI::: 25) and obese (BMI 
> 30) adult patients with OSA (AHI::: 5) were the targeted population for this study, as 
their risk of comorbidities are greater than those non-overweight/obese OSA patients. 
Sleep activity, wake activity and energy expenditure were measured prior and subsequent 
to initiating CPAP therapy, testing for differences that exist before and after therapy over 
time. A conceptual model (Figure 1, p. 5) was developed to provide the framework for 
assessing overweight/obesity (BMI), OSA (polysomnography-AHI), sleep activity 
(actigraphy), wake activity (actigraphy), energy expenditure (actigraphy) and CPAP 
compliance (internal compliance meter). The propositions linking these variables 
included the relationships between overweight/obesity and OSA, how sleep 
fragmentation/disruption and daytime fatigue/sleepiness are associated with OSA, and 
how these concepts link OSA to increased sleep activity and decreased wake activity, 
with a decrease in 24-hour total energy expenditure. The model further included CP AP 
treatment affecting sleep consolidation (less sleep fragmentation/disruption), improving 
wakefulness (less daytime fatigue/sleepiness), and how (respectively) these concepts 
negatively correlate CPAP treatment (and level of compliance) with sleep activity, and 
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positively correlate CP AP therapy with wake activity and 24-hour total energy 
expenditure. 
Findings 
As stated in the hypotheses, and following the conceptual framework, the net loss 
of total 24-hour sleep activity and gain in total 24-hour wake activity was expected to 
result in an overall increase in total 24-hour energy expenditure following CP AP 
treatment; however, the statistical analyses demonstrated the following findings relative 
to the 3 hypothesized study outcomes. 
Hypothesis I 
The first study hypothesis stated that subjects would have a decrease in sleep 
activity as a result of using CP AP, with decreases in 24-hour total sleep activity, both 7 
days and 30 days post CPAP, as compared to pre-CPAP. The results actually showed the 
following: 
HI) Subjects had a statistically significant increase in sleep activity as a result of 
using CPAP (measured by the Actiwatch®) 
Hla. compared to pre-CPAP, there was a statistically significant increase in 
24-hour total sleep activity (time in minutes) 7 days post-CPAP 
HIb. compared to pre-CPAP, there was a statistically significant increase in 
24-hour total sleep activity (time in minutes) 30 days post-CPAP 
The results demonstrated statistically significant increases in total 24-hour sleep 
activity, in minutes, from the pre-CPAP time point (baseline) to both the one week and 
30 day post-CPAP time points. Contrary to what was hypothesized, the subjects in this 
study showed a statistically significant increase in their 24-hour sleep activity, with 
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statistically significant differences between the CP AP compliant and noncompliant 
groups. When paired t-tests were performed from Tl to T2, the total group (n=38) and 
the CP AP compliant group (n=27) had statistically significant mean differences in sleep 
activity. While from TI-T3, it was the total group (n=35) and noncompliant group (n=14) 
who had statistically significant differences in mean sleep activity. 
At baseline, all subjects were exceeding 8 hours (>480 minutes) of sleep activity 
time over 24 hours (see Tables 9 and 10), with a minimum mean sleep time of 501.8 
minutes. They continued to exceed 8 hours and extend their 24 hour total sleep activity 
time following CP AP treatment at the seven day and 30 day time points. A graph (Figure 
3, p. 84) generated from repeated measures ANOVA further illustrates this point and 
shows group differences, with noncompliant subjects having more sleep activity time at 
each of the three time points as compared to the compliant subjects. There are no 
empirical studies to either support or negate these findings, only anecdotal references and 
clinical observations to offer mixed thoughts about the effect of using CP AP on sleep 
time. Clinically, patients report sleeping fewer hours and feeling more refreshed, so it is 
difficult to determine ifthese study subjects were sleeping longer as a consolidated sleep 
period at night or had more total sleep activity time because they were more sedentary or 
napping during the day, at any of the measured time points. This is a limitation of using 
actigraphy alone to measure ambulatory sleep activity for this study; however, this device 
has demonstrated reliability in distinguishing sleep and wake when compared to 
electroencepaholgraphic measures with polysomonography, and the results can be 
interpreted with a fairly high degree of confidence (Ancoli-Israel, 2005; Kushida et aI., 
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2001; Babin, Lee, Halko, Boudreau & George, 1997; Blood, Sack, Percy & Pen, 1997; 
Oakely, 1997; Sadeh, Hauri, Kripke & Lavie, 1995). 
Hypothesis 2 
The second study hypothesis stated that subjects would have an increase in wake 
activity as a result of using CP AP, with increases in 24-hour total wake activity, both 7 
days and 30 days post CPAP, as compared to pre-CPAP. The results actually showed the 
following: 
H2) Subjects had a statistically significant decrease in wake activity as a result of 
using CPAP (measured by the Actiwatch®) 
H2a. compared to pre-CP AP, there was a statistically significant decrease in 
24-hour total wake activity (time in minutes) 7 days post-CPAP 
H2b. compared to pre-CP AP, there was a statistically significant decrease in 
24-hour total wake activity (time in minutes) 30 days post-CPAP 
Again, contrary to what was hypothesized, the subjects in this study showed a 
statistically significant decrease in their 24 hour wake activity. Results of repeated 
measures ANOV A detected statistically significant group (compliant and noncompliant) 
and time differences in total 24 hour wake activity (in minutes) from the pre-CP AP time 
point (baseline) to both the one week and 30 day post-CPAP time points without 
significant interaction between groups or time points. Because there were only two 
groups, post-hoc testing was not conducted. Likewise, because there was no evidence of 
statistically significant interaction between groups and time, further data analyses was not 
performed. Interestingly, paired t-tests revealed the total group (n=38) from T1 to T2 and 
compliant group (n=27) to have statistically different mean wake activity times, but from 
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Tl to T3 the total group (n=35) and noncompliant group (n=14) showed statistically 
different wake activity time means. From baseline through T2, the compliant subjects had 
more mean wake activity time (and less mean sleep activity time) than the noncompliant 
subjects, which was just the opposite from baseline to T3. This finding is not fully 
understood and cannot be explained by differences in the demographic data collected, as 
there were no statistically significant differences between groups. Further exploration of 
this should be considered in future studies. 
Hypothesis 3 
The third study hypothesis stated that subjects would have an increase in energy 
expenditure as a result of using CP AP, with increases in 24-hour total energy 
expenditure, both 7 days and 30 days post CP AP, as compared to pre-CP AP. The results 
actually showed the following: 
H3) Subjects had a decrease (not statistically significant) in energy expenditure 
subsequent to initiating CP AP therapy (measured by the Actical®) 
H3a. compared to pre-CPAP, there was a decrease (not statistically 
significant) in 24-hour total energy (kilocalorie) expenditure 7 days post-
CPAP 
H3b. compared to pre-CPAP, there was a decrease (not statistically 
significant) in 24-hour total energy (kilocalorie) expenditure 30 days post-
CPAP 
Energy expenditure was not found to have a statistically significant time effect; 
therefore the study hypothesis for this outcome was not supported; however, repeated 
measures ANOV A detected statistically significant group differences among the CP AP 
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compliant and noncompliant (see Table 8). Paired t-tests were performed (Tables 9 and 
10), but were unable to confirm any statistically significant differences in EE in the total, 
compliant, and noncompliant groups, across any time point. Number of calories burned 
decreased, rather than increased, for both the CP AP compliant and noncompliant groups 
from T1 to T2 and T1 to T3, with the compliant group expending more energy than the 
noncompliant group at all time points. 
Conclusions 
These study findings were the opposite of what was hypothesized, with increased 
total 24-hour sleep activity time, decreased total 24-hour wake activity time, and 
decreased total 24-hour energy expenditure, regardless of CP AP treatment or level of 
compliance. The groups had statistically significant mean differences in sleep activity and 
wake activity from pre-CP AP to post-CP AP at one week and one month; however the 
direction of change was consistent for both groups, with sleep activity increasing and 
wake activity decreasing. At baseline, and continuing through T2 and T3, the CP AP 
compliant group showed less sleep activity, more wake activity, and more calories burned 
than the noncompliant group. When assessing demographics of the compliant versus 
noncompliant groups, there were no significant differences in any of the variables tested 
to account for this finding. 
CP AP compliance was an important variable in this study and has a wide degree 
of variance in the literature, with ranges from 46 to 80% (Basner, 2007; Grunstein, 2005; 
Kribbs et aI., 1993; Weaver et aI., 1997). In this study, approximately 71 % were 
compliant after the first week of home use, and approximately 60% were compliant after 
one month of home use. While not expected, subjects in this study had greater sleep 
97 
activity, less wake activity, and expended less energy after using CPAP, whether they 
were compliant or not. Empiric evidence has shown CP AP to decrease the number of 
arousals and awakenings during sleep due to apneic events; however, this did not 
translate to more consolidated/less total 24 hour sleep or greater 24 hour wake time/more 
physical activity for this group of study participants. Furthermore, these findings showed 
fewer calories burned post-CPAP, but differences in energy expenditure were not 
statistically significant. 
Unfortunately there is no direct link to or succinct explanation for this study's 
findings; however, two relatively recent publications by West, Kohler, Nicoll, & 
Stradling (2009) and Otake et al. (2010) studied the effect of CP AP on sleep/wake 
activity using actigraphy. West et al. studied 36 men with OSA and found there were no 
significant differences in activity levels one week before the initiation of CP AP as 
compared to one week after CPAP therapy. Otake et al. confirmed agreement between 
PSG and actigraphy data and determined subjects treated after one month of CP AP had 
significantly less activity levels/movement than prior to CPAP. Both the effects of OSA 
and CP AP therapy on sleep/wake activity and energy expenditure remain unclear and 
lack sufficient empirical evidence to support the current study results. 
This study has shown that OSA subjects using CP AP have more sleep activity 
than prior to treatment, subsequently reducing 24-hour total wake activity time. Less 
wake time, combined with fewer arousals and awakenings due to apnea, could feasibly 
reduce total caloric expenditure. Although there was not a statistically significant 
decrease in daily energy expenditure following CP AP use, the decline in calories burned 
following CP AP treatment may be a longer term factor in weight gain for OSA patients. 
98 
Implications 
This research was adequately powered to demonstrate that CP AP use is a 
statistically significant factor affecting sleep activity time, wake activity time, and energy 
expenditure. Regardless ofCPAP compliance (nightly hours) and length of use (one 
week or one month), the entire post-CP AP group demonstrated more sleep activity, had 
less wake activity, and burned fewer calories. This would potentially translate to an 
increase in weight over time. From a clinical perspective, the results of this study do not 
support the use of CP AP as a potential weight loss measure in overweight and obese 
OSA patients, and emphasize the need for the inclusion of behavioral weight 
management and weight loss strategies in an at-risk population for comorbid illnesses. 
The extended use of actigraphy in both the research and practice setting would be a 
beneficial adjunct to monitoring sleep/wake activity and energy expenditure and set 
behavioral goals and outcomes. Studies have shown that those who self-report sleeping 
fewer hours (.:::..6 hours/day) tend to gain weight (Hayes, Xu, Babineau, & Patel, 2011; ) 
and have higher incidences of circulating leptin (adipose-derived hormone) and 
adipokines (immunomodulating cytokines secreted by adipose tissue) levels (Hayes, et 
al.). These high levels have been linked to greater risk of increased inflammatory markers 
contributing to cardiovascular and cerebrovascular disease, insulin resistance, and 
diabetes (Leinum, Dopp, & Morgan, 2009; Vgontzas, Zoumakis, & Bixler, 2004); Patel, 
Zhu, & Storfer-Isser, 2009). 
The current study showed those who completed the study (n=35) were older and 
had a lower BMI than those who did not complete the study (n=15). These were the only 
statistically significant differences among demographics. The outcomes of this study 
99 
may have been quite different had the 30% early-term subjects completed the study. This 
is also an important consideration for recruitment and retention for future research. Of 
the entire completed sample (n=35), there were no statistically significant differences in 
demographic findings between those who were compliant with CP AP and those who 
were not. Interestingly, those who completed all 3 time points averaged more than 8 
hours of sleep both before and after CP AP treatment. This could be a result of actigraphy 
recording sleep during waking sedentary activity. Possibly, previous research utilizing 
subjective sleep report may underestimate true sleep time. Again, this may support the 
use of actigraphy in combination with subject sleep/wake diaries in both research and 
practice. 
Limitations 
While those patients who are unable to speak, read, write and understand the 
English language were excluded from study participation, this did not pose a significant 
restriction to recruitment, as the practice setting this sample was drawn from does not 
typically have a high percentage of non-English speaking patients. However, external 
validity and generalizability was limited for several reasons. Choosing only one practice 
setting had the disadvantage of not having a more heterogeneous group, and including 
only one group did not allow for a control group or group comparisons, other than 
compliance. For this study, the inclusion of several sites and patient groups was cost 
prohibitive and not feasible without additional research staff. Conversely, an advantage 
to a single site and group was efficiency, consistency and better control of patient care 
and follow-up, diagnostic testing, scoring of data, and titration of CP AP. 
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To reduce threats to internal validity, acknowledgement and control of as many 
identified confounding variables as possible was exercised; however, the apparent 
Simpson's Paradox observed during data analyses revealed the likely influence of such 
variables. Some of these variables were anticipated and accounted for in the 
inclusion/exclusion criteria and CP AP compliance data. The use of subjective sleep 
diaries, and activity and food diaries (during the days of Actiwatch® and Actical® use) 
would have offered further support and/or explanation of data and should be considered 
in future studies. Additionally, ANOVA assumes subjects will be randomly assigned to 
either a control or treatment group, so that two groups do not have any systematic 
difference except for the treatment applied. This study design involved non-random 
assignment; however, in the case of self-selection, the repeated measures treatment effect 
model was expected to produce reliable estimates of the mean differences. 
The study was further limited by the possibility that pre- and post-CPAP 
differences in sleep/wake activity and energy expenditure may be detected as a result of 
subject response to study participation and knowledge of what is being measured rather 
than real change (Munro, 2005). A repeated measures study design was expected to 
provide some control against such contrived patient activity, or even variation in activity 
levels related to individual and situational factors at the time of measurement. An 
extension of this longitudinal study may have offered more robust findings. 
Recommendations 
Research in the area of sleep/wake and energy expenditure in overweight and 
obese OSA patients has become increasingly important and clinically relevant in a 
population where the incidence of OSA, weight gain, and resulting comorbid illness 
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continues to rise (Leinum, Dopp, & Morgan, 2009). There is an abundance of evidence 
linking OSA, obesity, cardiovascular disease, metabolic risk, and the benefit of CP AP 
therapy; however, there is limited data regarding the effect CPAP treatment has on sleep, 
wake, and energy expenditure in an ambulatory and long-term setting. Although the 
results of this study failed to support the conceptual framework developed to guide the 
study hypotheses, this study offers a substantial review of past and currently available 
literature and provides a foundation for future clinical investigation. The current 
conceptual framework and hypotheses were developed from the existing body of 
knowledge in this field which was heavily weighted on anecdotal studies and clinical 
observation, further highlighting the need for greater empirical testing. Additional 
research in overweight and obese patients with OSA is needed, and should be pursued 
with model revision of sleep/wake and energy expenditure concepts that link OSA with 
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Title: SleepM'ake Activity and Energy Expenditure in Overweight and 
Obese Adults with Obstructive Sleep Apnea: A Pre- and Post-CPAP 
Comparison 
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6 7/6/2008 12:00:00 PM m12008 12:00:00 PM 424050 294.48 1640 
7 7rr12008 12:00:00 PM 71812008 12:00:00 PM 299030 207.66 1858 
8 7/8/2008 12:00:00 PM 71812008 1:16:30 PM 5572 72.84 723 
n . . . 8 8 8 
Averageln) 300488,76 22D.43 1899.62 
Std DevIn-I) 131775.19 69.07 751.86 
Q2l1! %lnvalldAC "&!Invalid llW %Wake SleepTlme %Sleap 
(%) (%) (%) (minutes) (%) 
1 0.00 0.16 58.02 531.00 41.98 
2 0.00 0.00 64.85 35:14 
3 0.00 0.00 74.10 25.90 
4 0.00 0.00 68.09 31.91 
5 0.00 0.00 60.42 39.58 
6 0.00 0.00 6B.44 31.56 
7 0.00 0.00 60.42 39.58 
8 0.00 2.61 15.00 20.13 79.87 
n 8 8 B 8 8 
Averageln) 0.00 0.35 807.00 59.31 40.69 
Std Dev(n-l) 0.00 0.92 335.14 16.69 15.59 
Printed: 7/812008, 1:21:29 PM Mini Mltter Company, Inc. Page 4 
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1 Study #: I 9080 
Appendix G 
Obstructive Sleep Apnea Polysomnography Report 
Sleep Medicine SI1ecia1ists 
1169 Eastern Parkway, Suite #3357 




Date of bIrth: 
Physidan: Dr. David Winslow 
Axis A/ICSD: 780.53-0 
1 Patient ID #: 1120922 
Dear.' •• 
We appreciate your referral of this patient to our services for Polysomnography. The 15 channel overnight study 
consists of a combination of EEG, Chin EMG, EOG, leg EMG, thoradc and abdomInal wall movements, nasal/oral 
airflow, ECG, Sa02, body position, and tracheal sound. The results are as follows: 
I Age: 1 44 I Weight: 1 2061bs. I Height: I Sft:.l0in. 
Medications: Reglan,Protonlx,Lexapro 
Sleep Staging 
I Ughts Out: 11:04:47 PM 1 Lights On: 1:16:47 AM 
Sleep stage Sleep duration % of time in bed Normal values 
Stage N1 2.5 min. 1.9 % (5%) 
Stage N2 99.0 min. 75.0 % (50%) 
StaQe N3 (delta) 11.5 min. 8.7 % (15%1 
Stage R (REM) 0.0 mIn. 0.0 % (20%) 
Stage W (wake) 19.0 min. 14.4 % (10%) 
Respiratory 
Aoneas 
Central Obstructive Mixed HypClJ:!neas Total 
I 41 of events 0 42 0 113 155 
I Mean duration 0.0 18.9 0.0 21.3 
I Max. duration 0.0 24.5 0.0 41.5 





Duration (min.) 0/0 asleep 
Uo 






Rieht Side 36.2 95.3 
~==~~~~7::":----+--=~-+~ Minimum 02 Value 
Heart Rate 
Mean Heart Rate (BPM) 
Lowest Heart Rate (BPM) 
Hlehest Heart Rate BPM 
Total number of WK or MVf episodes 
Arousal index 


















Sleep Medicine Specialists 
1169 Eastern Parkway, Suite #3357 




The patient tolerated NPSG well with loud snoring and OSA observed. There were a total of 155 
respiratory abnormalities with an apnea/hypopnea index (AHI) of 82.3 (average number of apneas/ 
hypopneas per hour of sleep-a value greater than 5.0 is considered abnormal). Oxygen saturation 
dropped to 77% during the recording. ECG recording revealed no ECG abnormalities. The patient will 
follow up with Dr. David Winslow for sleep study results. 
Physician's Impression: Very Severe Obstructive Sleep Apnea Syndrome 
Physidan's Signature: _-1>[£<-1-,' \ .... d<....;;;--'~c;,..;.;. _________ _ 
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Appendix H 
CP AP Titration Polysomnography Report 
Sleep Medicine Specialists 
1169 Eastern Parkway, Suite #3357 





I Age: 44 years I Welght:206Ibs. I Height: Sft.101n. 
Medications: Reglan,Protonlx,Lexapro 
SleeP Staging 
I Ughts Out: 1:18:47 AM 
Sleep stage Sleep duration 
StageNl 9.5 min. 
Stage N2 146.0 min. 
StaQe N3 (delta) 50.0 min. 
Stage R (REM) 55.0 min. 








I Ughts On: 6:01:47 AM 
'Yo of time in bed Normal values 
3.4 'Yo (5%) 
51.6 % (50%) 
17.7 % (15%) 
19.4 'Yo (20%) 
8.0 % (10%) 
Minimum 02 value: 







Lowest Pressure Tried: 5 em H20 
em H20 Highest Pressure Tried: 12 
Final Optimal Pressure: 9 cmH20 
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~:d_ 
Sleep Medicine SpedaI1sts 
1169 Eastern Parkway, Suite #3357 




CPAP was titrated to a pressure of 9 em/H20 with no significant GSA obsesved, and the patient tolerated CPAP 
well. It is recommended that the patient follow up with Dr. David Winslow within one month for CPAP 
compliance therapy. 




CP AP Compliance Report 
Sleep Medidne Specialists 
1169 Eastern Parkway 
Suite 3310 
Louisville, Ky 40217 United States 
Device: REMstar Auto M Series with A-Flex ( SlOM ) 
Compliance Details - Full Report 
Interaction Date: 7/8/200812:~8 PM 











Compliance Information 7/1/2008 - 7/7/2008 
20 ...... (\y~rqg~H.u.n)I9l.fi.er .~~ttlpg; .2 .. 9, ~~~ ?!!\t.IIJ9 :. ? ...... __ . ... .. .. _ .... ........... . ... .. .... ... ...... . ......... . 
" '" " :OS 
Average Flex Setung: 3.0, Last Setting: 3 
..... -tPAp.wltflC-flex . . .. . . . . . . . . . . . . .. . . ..... . .......... . . . .......... . . . . ........ . .. . ........... . J ..... . 
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Appendix K 
Data Collection Forms 
Visit 1.0 (Initial Sleep Evaluation, Pre-CPAP) 
Date of Visit: ______________ _ 
Informed Consent Process: 
Date ofInformed Consent: Version: ---------------------- ----------------
Study procedures, risks, benefits, and other relevant study information were explained to the 
subject. Subject was allowed to ask questions and all questions were answered completely by 
assigned study staff. Subject was given a copy of the signed ICF. The subject signed the ICF 
prior to the performance of any study-related procedures. 
y N Checklist: 
Subject is able to read, write, and comprehend the English language? 
Subject read and verbalized understanding of the informed consent? 
Adequate time was allowed? 
All questions were answered to the subject's satisfaction? 
Subject signed and dated the informed consent? 
A copy was provided to subject for his/her records? 
Individual conducting consent process: _____________________________ D.ate: ______ _ 
Date of Birth: ____________ Age: 





American Indian or Alaskan Native 
Native Hawaiian or Other Pacific Islander 
___ (18-65) 








Education level: (highest level obtained) 
<12 years 
High School Diploma (12 years) 
TechnicalN ocational School 
CollegelUniversity Undergraduate (14 years) 
CollegelUniversity Undergraduate (16 years) 
CollegelUniversity Graduate (18 years) 





















Other (specify): ____________________ _ 
Any acute, unstable, or untreated medical conditions? 
Yes: ---------------------------
No 
Height: __ "_in ___ " cm 
Weight: __ _ lbs 
BM!: kg.;-~m)2= __ _ 
(weight kg) .;- [height (m)]2 
142 
Child-bearing Potential: Female of childbearing potential? 
Yes/No: ------------------ N/A: ________ _ 
Urine Pregnancy Test Results: Positive/Negative N/A 
Expiration/Lot #: ________________ __ 
Eligibility Review: (all must be marked yes, "Y", for study inclusion) 
1 ) male or female; 
2) adults age 18 to 65; 
3) able to speak, read and write the English language; 
4) overweight or obese (BMI ~25); 
5) initially present with signs and symptoms consistent with OSA, which is newly and 
diagnostically confirmed with an AHI ~5 as determined by PSG; 
6) require CP AP therapy (physician-prescribed); 
7) maintain traditional work hours (no night shift work); 
8) go to bed between 9:00 pm and 1 :00 am, allowing 6 to 9 hours of sleep time; 
9) no known acute, unstable, or untreated medical conditions; and 
10) not pregnant or planning to become pregnant. 
Actigraphy: 
Subject instructed on the use of the Actiwatch® and Actical® devices: 
Yes/No -----------------
Actiwatch® dispensed: ______________ _ 
Actical® dispensed: ________________ _ 
Subject asked to wear both wrist devices 24 hours a day (without removing) for ten days prior to 
their scheduled diagnostic PSG: Yes/No --------------
Diagnostic PSG scheduled per SMS clinical staff: 
Yes: Date of PSG: -------------
No: Explain: ______________ __ 
Signature of individual completing source documents Date 
143 
Visit 2.0/2.1 (Diagnostic PSG/CP AP Titration) 
Date of Visit: ______________ _ 
PSG: 
Split diagnostic/CPAP titration 
Diagnostic only 
ApneaIHypopnea Index: ___ _ 
CPAP Titration PSG scheduled per SMS clinical staff: 
Yes: Date ofCPAP Titration PSG: ___________ _ 
No: Explain: _____________ _ 
N/A 
CP AP Pressure: _____ cm H2O 
Eligibility Review: (must be marked yes, "Y", for study inclusion) 
• OSA diagnostically confirmed with an AHI ~5 as determined by PSG; 
• require CP AP therapy (physician-prescribed); 
Actigraphy: 
Subject returned Actiwatch® and Actical® devices: YeslNo ----------
Actiwatch® data downloaded: start date. _______ .....;/end date _______ _ 
Day 1: Total sleep minutes: _____ Total wake minutes:. _____ _ 
Day 2: Total sleep minutes: _____ Total wake minutes: _____ _ 
Day 3: Total sleep minutes: _____ Total wake minutes: _____ _ 
Day 4: Total sleep minutes: _____ Total wake minutes: _____ _ 
Day 5: Total sleep minutes: _____ Total wake minutes: _____ _ 
Day 6: Total sleep minutes: _____ Total wake minutes: _____ _ 
Day 7: Total sleep minutes: _____ Total wake minutes: _____ _ 
Day 8: Total sleep minutes: _____ Total wake minutes: _____ _ 
Day 9: Total sleep minutes: _____ Total wake minutes: _____ _ 
Day 10: Total sleep minutes: _____ Total wake minutes: _____ _ 
144 
Actical® data downloaded: start date. _______ --'/end date, ________ _ 
Day 1: Total EE:, _____ _ 
Day 2: Total EE:, _____ _ 
Day 3: Total EE:, _____ _ 
Day 4: Total EE:, _____ _ 
Day 5: Total EE:, _____ _ 
Day 6: Total EE: _____ _ 
Day 7: Total EE: _____ _ 
Day 8: Total EE: _____ _ 
Day 9: Total EE: _____ _ 
Day 10: Total EE:, _____ _ 
Adverse Events: (related to study participation and/or procedures) 
yes: _______________________________ _ 
No 
CP AP set-up scheduled per SMS clinical statT: _______ _ 
Comments: 
Signature of individual completing source documents Date 
145 
Visit 3.0 (CPAP Set-Up, Post-CPAP) 
Date of Visit: ______________ _ 
Actigraphy: 
Subject instructed on the use of the Actiwatch® and Actical® devices: 
Yes/No -----------------
Actiwatch® dispensed: ___________ __ 
Actical® dispensed: ______________ _ 
Subject asked to wear both wrist devices 24 hours a day (without removing) for approximately 40 
days starting with the first day of CPAP use at home: Yes/No ________________ _ 
CPAP: 
CPAP compliance card included with CPAP equipment: Yes/No ________________ _ 
Adverse Events: (related to study participation and/or procedures) 
Yes: _______________________________________________________________ _ 
No 
One Month Follow-Up visit scheduled per SMS clinical statT: _______ _ 
Comments: 
Signature of individual completing source documents Date 
146 
Phone Contact (Post-CPAP, At Home) 
Date of Phone Contact: ________ _ 
Actigraphy: 
Assess use of Actiwatch® and Actical® devices at home: YeslNo ----------------
Comments: -----------------------------
CPAP: 
Assess use ofCPAP at home: YeslNo ----------
Comments: _____________________________ __ 
Adverse Events: (related to study participation and/or procedures) 
Yes: _______________________________ ___ 
No 
Confirm One Month Follow-Up visit scheduled per SMS clinical staff: _______ _ 
Comments: 
Signature of individual completing source documents Date 
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Visit 4.0 (One month Post-CP AP) 
Date of Visit: ______________ _ 
Actigrapby: 
Subject returned Actiwatch® and Actical® devices: Yes~o ______________ __ 
Actiwatcb® data downloaded: start date, _______ ~/end date, _______ _ 
Day 1: Total sleep minutes: ______ Total wake minutes: _________ __ 
Day 2: Total sleep minutes: ______ Total wake minutes: ________ _ 
Day 3: Total sleep minutes: _______ Total wake minutes: _________ __ 
Day 4: Total sleep minutes: ______ Total wake minutes:, _________ __ 
Day 5: Total sleep minutes: _______ Total wake minutes: _______ _ 
Day 6: Total sleep minutes: _____ Total wake minutes: _____ _ 
Day 7: Total sleep minutes: ______ Total wake minutes: _____ _ 
Day 8: Total sleep minutes: _____ Total wake minutes: _____ __ 
Day 9: Total sleep minutes: _____ Total wake minutes: _____ __ 
Day 10: Total sleep minutes: _____ Total wake minutes: _____ _ 
Day 11: Total sleep minutes: _____ Total wake minutes: _____ __ 
Day 12: Total sleep minutes: ______ Total wake minutes: ______ _ 
Day 13: Total sleep minutes: _____ Total wake minutes: ______ _ 
Day 14: Total sleep minutes: ______ Total wake minutes:, ______ _ 
Day 15: Total sleep minutes: ______ Total wake minutes:, ______ _ 
Day 16: Total sleep minutes:, ______ Total wake minutes:, ______ _ 
Day 17: Total sleep minutes:, _______ Total wake minutes: _____ _ 
Day 18: Total sleep minutes:, _______ Total wake minutes: _____ _ 
Day 19: Total sleep minutes: _____ Total wake minutes: ______ _ 
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Actiwatch® data downloaded (continued): start date ____ ....:/end date _____ _ 
Day 20: Total sleep minutes: _____ Total wake minutes: _____ _ 
Day 21: Total sleep minutes: Total wake minutes: _____ _ 
Day 22: Total sleep minutes: Total wake minutes: _____ _ 
Day 23: Total sleep minutes: Total wake minutes: _____ _ 
Day 24: Total sleep minutes: Total wake minutes: _____ _ 
Day 25: Total sleep minutes: Total wake minutes: _____ _ 
Day 26: Total sleep minutes: Total wake minutes: _____ _ 
Day 27: Total sleep minutes: Total wake minutes: _____ _ 
Day 28: Total sleep minutes: Total wake minutes: _____ _ 
Day 29: Total sleep minutes: Total wake minutes: _____ _ 
Day 30: Total sleep minutes: Total wake minutes: _____ _ 
Day 31: Total sleep minutes: Total wake minutes: _____ _ 
Day 32: Total sleep minutes: Total wake minutes: _____ _ 
Day 33: Total sleep minutes: Total wake minutes: _____ _ 
Day 34: Total sleep minutes: Total wake minutes: _____ _ 
Day 35: Total sleep minutes: Total wake minutes: _____ _ 
Day 36: Total sleep minutes: Total wake minutes: _____ _ 
Day 37: Total sleep minutes: Total wake minutes: ------
Day 38: Total sleep minutes: Total wake minutes: _____ _ 
Day 39: Total sleep minutes: Total wake minutes: _____ _ 
Day 40: Total sleep minutes: Total wake minutes: _____ _ 
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Actical@datadownloaded:start date, _______ /end date, ________ _ 
Day 1: Total EE: Day 21: Total EE:, _____ _ 
Day 2: Total EE: Day 22: Total EE:, _____ _ 
Day 3: Total EE: Day 23: Total EE:, _____ _ 
Day 4: Total EE: Day 24: Total EE:, _____ _ 
Day 5: Total EE: Day 25: Total EE:, _____ _ 
Day 6: Total EE: Day 26: Total EE:, _____ _ 
Day 7: Total EE: Day 27: Total EE: _____ _ 
Day 8: Total EE: Day 28: Total EE: _____ _ 
Day 9: Total EE: Day 29: Total EE: _____ _ 
Day 10: Total EE: Day 30: Total EE: _____ _ 
Day 11: Total EE: Day 31: Total EE: _____ _ 
Day 12: Total EE: Day 32: Total EE: _____ _ 
Day 13: Total EE: Day 33: Total EE: _____ _ 
Day 14: Total EE: Day 34: Total EE: _____ _ 
Day 15: Total EE: Day 35: Total EE: _____ _ 
Day 16: Total EE: Day 36: Total EE: _____ _ 
Day 17: Total EE: Day 37: Total EE:. _____ _ 
Day 18: Total EE: Day 38: Total EE:. _____ _ 
Day 19: Total EE: Day 39: Total EE: _____ _ 
Day 20: Total EE: Day 40: Total EE:, _____ _ 
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CPAP: 
Subject provided CPAP compliance card: yes/No ________ _ 
CP AP compliance data downloaded: start date ______ ....;'end date ______ _ 
Day 1: Hours of use: ______ _ Day 21: Hours ofuse: ______ _ 
Day 2: Hours ofuse: ______ _ Day 22: Hours ofuse: ______ _ 
Day 3: Hours of use: ______ _ Day 23: Hours of use: ______ _ 
Day 4: Hours ofuse: ______ _ Day 24: Hours ofuse: ______ _ 
Day 5: Hours of use: ______ _ Day 25: Hours ofuse: ______ _ 
Day 6: Hours ofuse: ______ _ Day 26: Hours of use: ______ _ 
Day 7: Hours ofuse: ______ _ Day 27: Hours ofuse: ______ _ 
Day 8: Hours ofuse: ______ _ Day 28: Hours ofuse: ______ _ 
Day 9: Hours of use: ______ _ Day 29: Hours ofuse: ______ _ 
Day 10: Hours of use: ______ _ Day 30: Hours ofuse: ______ _ 
Day 11: Hours of use: ______ _ Day 31: Hours of use: ______ _ 
Day 12: Hours ofuse: ______ _ Day 32: Hours ofuse: ______ _ 
Day l3: Hours ofuse: ______ _ Day 33: Hours ofuse: ______ _ 
Day 14: Hours ofuse: ______ _ Day 34: Hours ofuse: ______ _ 
Day 15: Hours ofuse: ______ _ Day 35: Hours ofuse: ______ _ 
Day 16: Hours ofuse: ______ _ Day 36: Hours ofuse: ______ _ 
Day 17: Hours ofuse: ______ _ Day 37: Hours ofuse: ______ _ 
Dayl8: Hours ofuse: ______ _ Day 38: Hours ofuse: ______ _ 
Day 19: Hours ofuse: ______ _ Day 39: Hours ofuse: ______ _ 
Day 20: Hours ofuse: ______ _ Day 40: Hours ofuse: ______ _ 
Adverse Events: (related to study participation and/or procedures) 
yes: _________________________________ _ 
No 
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End of Study 
Comments: 





Pamela Ann McCullough, M.S.N., A.P.R.N. 
1169 Eastern Parkway, Suite 2243 




2008-present Doctoral Candidate 
School of Nursing, University of Louisville, Louisville, Kentucky 
2006-2008 Ph.D. Student 
School of Nursing, University of Louisville, Louisville, Kentucky 
1997 M.S.N., Adult Nurse Practitioner 
School of Nursing, University of Louisville, Louisville, Kentucky 
1991 B.S.N. 
School of Nursing, University of Louisville, Louisville, Kentucky 
Certifications & Licensure 
Kentucky Registered Nurse, License #1068451 
Kentucky Advanced Registered Nurse Practitioner, Registration #3002565 
ACRP Certified Clinical Research Coordinator, 2004 - present 
Basic Cardiac Life Support, 2004 - present 
Professional Employment 
2005-present Director of Clinical Research 
Kentucky Research Group 
Louisville, Kentucky 
2000-2005 Nurse Practitioner (clinical/research) 
Sleep Medicine Specialists/Chest Medicine Associates 
Louisville, Kentucky /F rankfort, Kentucky 
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1998-2000 Nurse Practitioner 
Sleep Disorders Center 
Audubon Hospital, Louisville, Kentucky 







Baptist Hospital East, Louisville, Kentucky 
Registered NurselNurse Practitioner (part-time) 
Hospital rounds/Office clinic 
Pulmonary and Internal Medicine Associates, Louisville, Kentucky 
Registered Nurse - Weekend Pulmonary Rounds (part-time) 
Physician group: Chest Medicine Associates 
Audubon Hospital, Louisville, Kentucky 
Nurse ClinicianlRegistered Nurse (full-time) 
Sleep Disorders Center 
Audubon Hospital, Louisville, Kentucky 
Staff Registered Nurse/Charge Nurse 
Cardiopulmonary/Oncology Unit 
Audubon Hospital, Louisville, Kentucky 
Nurse Extern/Patient Care Assistant 
Nursing Pool 
Audubon Hospital, Louisville, Kentucky 
Winslow, D. H., Bowden, C. H., DiDonato, K., McCullough, P. A., Day, W. W. 
(2010). A randomized, double-blind, placebo-controlled, parallel-group study of 
Phenterrnine/Topirarnate CR (VI-0521) for the treatment of obstructive sleep 
apnea/hypopnea syndrom in obese adults [Abstract]. Sleep Abstract Supplement, Abstract 
No. 0475. 
Roth, T. & McCullough, P.A. (2005). Understanding and managing insomnia. 
AANP Monograph. Wrightstown, P A: Medical Communications Media. 
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McCullough, P.A. (1999). Sleep and pregnancy. University of Louisville, 
Perinatal Coordinating Center News, 27(9). 
McCullough, P. A. (1998). Obstructive sleep apnea: does level of severity 
correlate with level of depression? Sleep Abstract Supplement. 
McCullough, P.A. (1988). Relating OSA and depression. The Journalfor Respiratory 
Care PractitionerslRT Magazine, 29-31. 
Presentations 
(Speaker, Invited) 
McCullough, P.A. Nursing Journal Review. Kentucky Sleep Society Annual 
Sleep Medicine Conference, Louisville, KY. 2007 & 2008. 
(Speaker, Invited) 
McCullough, P.A. How Well Do You Sleep? Kentucky Coalition of Nurse 
Practitioners and Nurse Midwives Annual Conference, Louisville, KY. 2001. 
(Speaker, Invited) 
McCullough, P.A. Optimizing Your Sleep. Speaking of Women's Health 
Conference, Louisville, KY. 2001. 
(Poster) 
McCullough, P.A. OSA and depression. Narcolepsy Conference, Chicago, IL. 
March 1999. 
(Poster) 
McCullough, P.A. Obstructive sleep apnea: does level of severity correlate with 
level of depression? Associated Professional Sleep Society Ith Annual Meeting, New 
Orleans, LA. June 1998. 
Professional Organizations 
Association of Clinical Research Professionals 
Kentucky Coalition of Nurse Practitioners and Nurse Midwives 
American Academy of Sleep Medicine 
Kentucky Sleep Society 
Continuing Education 
1994-present Associated Professional Sleep Society Annual Conference 
1999-present Kentucky Sleep Society Annual Meeting 












Obesity Drug Development Summit. Arlington, VA. 
Annual Association of Clinical Research Professionals Meeting 
Investigator Training for Medical Research. University of Rochester 
School of Medicine & Dentistry, Strong Memorial Hospital, and Western 
Institutional Review Board. Chicago, IL. 
Sleep-Disordered Breathing and CHF, Louisville, KY. 
Pediatric Conference for the Technologist, Louisville, KY. 
Workshop on the Sleep Needs, Patterns and Difficulties of Adolescents. 
Washington, D.C. 
Narcolepsy Conference, Chicago, IL. 
Annual KCNPNM Conference 
Regional Polysomnographic Technologist Conference, Chicago, IL. 
Polysomnographic Physician Course. The Sleep Disorders Center of 
Alabama. Birmingham, AL. 
Research Experience 
Industry-Sponsored Pharmaceutical Research 
Role: Sub-InvestigatorlResearch Coordinator 
20 II-present Boehringer Ingelheim 1245.20: A phase III randomised, double-blind, 
placebo-controlled parallel group efficacy and safety study of BI 10773 
and sitagliptin administered orally over 24 weeks, in drug naIve patients 
with type 2 diabetes mellitus and insufficient glycaemic control despite 
diet and exercise. 2011 - Ongoing 
Sanofi-Aventis EFC6058: TERACLESA multi-center double-blind 
parallel-group placebo-controlled study of the efficacy and safety of 
teriflunomide in patients with relapsing multiple sclerosis who are treated 
with interferon-beta 2011 - Ongoing. 
Novartis ACZ885H Study: 2361: A Randomized, Double-Blind, Active-
Controlled Study ofCanakinumab (ACZ885) Pre-Filled Syringes or 
Reconstituted Lyophilizate Versus Triamcinolone Acetonide for Treating 
Acute Gouty Arthritis Flares in Frequently Flaring Patients.2011-0ngoing. 
Merck 029: A Phase III, Multicenter, Randomized, Double-Blind, 
Placebo-Controlled, Parallel Group Study to Evaluate the Safety and 
Efficacy ofMK-4305 in Patients with Primary Insomnia. 2011 - Ongoing. 
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2010-present Forest LAS-MD-35: Long Term Safety and Tolerability of Aclidinium 
Bromide When Administered Twice Daily to Patients with Moderate to 
Severe Chronic Obstructive Pulmonary Disease. 2010 - Ongoing. 
Cephalon CI0953/4030: A Randomized, Double-Blind, Placebo-
Controlled Study to Evaluate the Efficacy and Tolerability of Armodafinil 
Treatment (150mg) in Improving Clinical Condition Late in the Shift and 
in Improving Functional and Patient-Reported Outcomes in Adult Patients 
With Excessive Sleepiness Associated With Shift Work Disorder. 2010. 
Eli Lilly H9X-MC-GBDC: The Impact of L Y2189265 Versus 
Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus 
(AWARD-3: Assessment of Weekly AdminstRation ofL Y2189265 in 
Diabetes-3) 2010 - Ongoing 
Eli Lilly H9X-MC-GBDN: The Effect ofLY2189265 on Blood Pressure 
and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in 
Patients with Type 2 Diabetes Mellitus. 2010 - Ongoing. 
Boehringer Ingelbeim 205.452: A Randomized, Active-Controlled, 
Double-Blind, Double-Dummy, Parallel Group Design, Multi-Center Trial 
to Compare the Efficacy and Safety of 2.5mg and 5 mg Tiotropium 
Inhalation Solution Delivered by the Respimat Inhaler with Tiotropium 
Inhalation Capsules 18mg Delivered by the HandiHaler. 2010 - Ongoing 
Philips Respironics: BiP AP autoSV Advanced in Central Apnea Patients 
2010 - Ongoing. 
2009-2010 Takeda AD4833_ 402: A Phase $, Randomized, Double-Blind, Placebo-
Controlled Study to Evaluate the Effect of Pioglitazone Compared to 
Placebo on Bone Metabolism in Impaired Fasting Glucose, 
Postmenopausal Women for 1 Year of Treatment 2009 - Ongoing. 
Pf"lzer A0081186: Randomized, double-blind 12-month Study of 
Pregabalin in Subjects with Restless Legs Syndrome. 2009-2010. 
Ventus C009-Aero: A prospective, multicenter parallel group, sham-
controlled, randomized, double-blinded clinical trial to compare the safety 
and effectiveness of the Pro vent Professional Sleep Apnea Therapy device 
to sham for the non-invasive treatment of obstructive sleep apnea. 2009-
2010. 
Sanof"l-Aventis EFC3014 GetGoalM: A Randomized, Double-Blind, 
Placebo-Controlled Parallel-Group, Multicenter, 24 week Study Followed 
by an Extention Assessing the Efficacy and Safety of AVE0010 on Top of 
Metformin in Patients with Type-2 Diabetes not Adequately Controlled 
with Metformin. 2009-0ngoing. 
Cephalon C10953-3067IES/MN: A 12-week, Randomized, Double-
Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage, Study to 
Evaluate the Efficacy and Safety of Armodafinil (50, 150, and 250 
mg/day) as Treatment for Patients With Excessive Sleepiness Associated 
With Mild to Moderate Closed Traumatic Brain Injury. 2009-2010. 
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Ventus C009E-Aero: A prospective, multicenter, single arm, open-label 
extension study to evaluate the long-term durability of treatment response 
and safety of the Provent Professional Sleep Apnea Therapy Devices for 
the non-invasive treatment of obstructive sleep apnea - hypopnea. 2009 -
2010. 
PfIZer A8801015: A Randomized Phase 2, Double-Blind, Placebo-
Controlled, Multi-Center, Crossover Study ofPF-03654745 as a Daily 
Treatment for Excessive Daytime Sleepiness (EDS) Associated with 
Narcolepsy. 2009-2010. 
PfIZer A0081165: Effects of Pregabalin on Sleep Maintenance in 
Subjects with Fibromyalgia Syndrome and Sleep Maintenance 
Disturbance: Randomized, Placebo-Controlled, 2-way Crossover 
Polysomnography Study. 2009 - 2010. 
Merck 009: A Phase III, Multicenter, Randomized, Double-Blind, 
Placebo-Controlled, Parallel-Group, Long Term Safety Study ofMK-4305 
in Patients with Primary Insomnia. 2009 - Ongoing. 
2008-2009 Merck 015: A Multicenter, Randomized, Double-Blind, Double-Dummy, 
Placebo and Modafinil Controlled, 3-Period Crossover, Adaptive Dose 
Design Study to Determine the Safety and Efficacy ofMK-0249 in 
Treating Excessive Daytime Sleepiness in Patients with Obstructive Sleep 
Apnea Using Nasal Continuous Positive Airway Pressure (nCPAP) 
Therapy. 
Arena APD125-007: A Randomized, Double-Blind, Placebo-Controlled 
Subjective Study to Assess the Efficacy of APD125 in Patients with 
Primary Insomnia Characterized by Difficulty Maintaining Sleep. 
PfIZer A0081183: Randomized, Double-Blind, 6 Week Study of 
Pregabalin in Subjects with Restless Leg Syndrome. 2008 - Ongoing. 
Sanofi EFC6909: A Double-Blind, Randomized, 12-Month, Placebo-
Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy 
and Safety of A VE5530 25mg/day and A VE5530 50mg/day in Patients 
with Primary Hypercholesterolemia. 
VIVUS OB-204: A Randomized, Double-Blind, Placebo-Controlled, 
Parallel-Group Study of VI -0521 for the Treatment of Obstructive Sleep 
ApnealHypopnea Syndrome in Obese Adults. 
Sanofi EFC10844/ECLIPSE: Efficacy and Safety of Eplivanserin 
5mg/day in Insomnia Characterized by Sleep Maintenance difficulties: A 
6-Week, Randomized, Double-Blind, Placebo-Controlled, 
Polysomnography Study. 
PfIZer A9001380: Refinement of Patient Reported Outcomes Instruments 
in Subjects with Insomnia Characterized by Non Restorative Sleep. 
2007-2008 Merck 079: Randomized, Double-Blind, Active-Comparator, Clinical 
Trial to Study the Efficacy and Safety ofMK-0431A for the Treatment of 
Patients with Type 2 Diabetes Mellitus (T2DM). 
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Vanda VP-VEC-162-3104: A Multicenter, Randomized, Double-Blind, 
Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety 
ofVEC-162 (20mg/day and 50 mg/day) in the Treatment of Primary 
Insomnia. 
SanofI-Aventis LTE6673/SAMS: Efficacy and Safety of2mg/day of 
MI00907 on Sleep Maintenance Insomnia with a Sub-Study of the effect 
ofMI00907 on Stable Type II Diabetes Mellitus: A One Year, Multi-
center, Randomized, Double- Blind, Placebo-Controlled Study. 
Pf'lZer A5351019: A 2-Year, Randomized, Double-Blind, Placebo-
Controlled Phase 3 Study to Evaluate the Long-Term Efficacy and Safety 
ofCP-945,598 in the Treatment of Obese Subjects. 
Organon 176001: A Two-Week, Double-Blind, Placebo-Controlled, 
Randomized, Parallel Group, Efficacy and Safety, Outpatient Trial with 
Org 50081 in Patients with Chronic Primary Insomnia. 
Organon 176004: Fifty-Two Weeks, Open-Label Extension Trial to 
Evaluate Safety and Efficacy of Org 50081 in Outpatients with Chronic 
Primary Insomnia who Completed Clinical Trial Protocol 176001 or 
176002. 
Takeda 01-06-TL-375-071: Randomization, Double-Blind, Placebo-
Controlled Study to Assess Whether the Administration of Ramelteon 
Could Facilitate the Discontinuation of Zolpidem (Ambien) > 1 Omg 
Therapy in Subjects with Chronic Insomnia. 
Vivus OB-301: A Phase III, Randomized, Double-Blind, Parallel-Design 
Study Comparing Multiple Doses ofVI-0521 to Placebo and Their 
Single-Agent Phentermine and Topiramate Constituents for the Treatment 
of Obesity in Adults. 
2007 Sanof'l-Aventis EFC60721N0ctume: Efficacy and Safety of2mg/day of 
MI00907 on Sleep Maintenance Insomnia: a 6-week, Multi-center, 
Randomized, Double-Blind, Placebo-Controlled Polysomnographic Study. 
Xenoport XP-081: A Randomized, Double-Blind, Placebo-Controlled 
Dose Response Study to Assess the Efficacy, Safety, and 
Pharmacokinetics of XP13512 in Patients with Restless Legs Syndrome. 
Merck V512-003: Validation of Patient Reported Outcome Measures for 
Influenza Disease for Use in Phase II POClPhase III Flu Peptide Vaccine 
Program. 
Xenoport XP083: A Randomized, Double-Blind, Active- and Placebo 
Controlled, Parallel Group Safety Study Assessing Simulated Driving 
Performance in XPl3512-Treated Patients with Restless Legs Syndrome. 
2006-2007 SanofI-Aventis EFC6220: Efficacy and Safety of Eplivanserin 5mg/day 
on Sleep Maintenance Insomnia: a 6-Week, Multicenter, Randomized, 
Double-Blind, Placebo-Controlled Study. 
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Merck 022-01: A Multicenter, Randomized, Double-Blind, "Factorial" 
Design Study to Evaluate the Lipid-Altering Efficacy and Safety ofMK-
0524B (dosed as coadministered MK-0524A and Simvastatin Tablets) in 
Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia. 
Novartis CVEA489A2302: An 8-Week, Multicenter, Randomized, 
Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of 
the Combination ofValsartanlHCTZ/Amlodipine Compared to 
ValsartanlHCTZ, ValsartaniAmlodipine, and HCTZ/Amlodipine in 
Patients With Moderate to Severe Hypertension. 
Merck 315: A Double-Blind, Randomized, Parallel, Efficacy Study 
Evaluating Losartan Potassium Alone or in Combination with 
Hydrochlorothiazide versus Placebo in Obese Patients with Elevated 
Systolic and Diastolic Blood Pressure. 
XenoPort, Inc. XP055: An Open-Label, 52-Week Extension Study 
Assessing XP 13 512 Safety and Efficacy in Patients with Restless Legs 
Syndrome. 
Takeda 01-05-TL-375-067: A Phase2, Double-Blind, Randomized, 
Placebo-Controlled, Parallel-Group, Multi-Center Proof-of-Concept Study 
to Evaluate the Safety and Efficacy of Ramelteon Taken in Combination 
with Doxepin for the Treatment of Subjects with Chronic Insomnia. 
GlaxoSmithKline 103660: A 12-Week, Multi-Center, Double-Blind, 
Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography 
Study of Ropinirole Controlled Release for Restless Legs Syndrome 
(RLS) in RLS Patients with Sleep Disturbance and Periodic Limb 
Movements (PLM) During Sleep. 
Merck 023: a Worldwide, Multicenter, Double-Blind, Randomized, 
Parallel Study to Evaluate the Efficacy ofMK-0524 to Improve 
Tolerability of Extended Release Niacin. 
XenoPort, Inc. XP052: A Randomized, Double-Blind, Placebo-
Controlled Study to Assess the Efficacy and Safety ofXP13512 in 
Patients with Restless Legs Syndrome. 
Schwarz SP793: An Open-Label Extension Trial to Investigate the Safety 
and Tolerability of Long-Term Treatment with Transdermal Rotigotine 
in Subjects with Idiopathic Restless Legs Syndrome. 
2006 Sanofi-Aventis LTE6262: Efficacy and Safety of Eplivanserin 5mg/day 
on Sleep Maintenance Insomnia: a 12-Week Multicenter, Randomized, 
Double-Blind, Placebo-Controlled Study Followed by an Open Treatment 
Phase Extension with Eplivanserin for a 40 Week Period. 
Merck 022: A Multicenter, Randomized, Double-Blind, "Factorial" 
Design Study to Evaluate the Lipid-Altering Efficacy and Safety of 
MK-0524B Combination Tablet in Patients With Primary 
Hypercholesterolemia or Mixed Hyperlipidemia. 
Merck 024: A Multicenter, Randomized, Double-Blind, Parallel Group, 
12 Week Study to Evaluate the Efficacy and Safety ofMK-0524B Versus 
Atorvastatin in Patients with Mixed Hyperlipidemia. 
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Takeda 01-0S-TL-37S-068: A Study of the Safety of Ramelteon with 
Moderate to Severe Chronic Obstructive Pulmonary Disease. 
200S-2006 Schwan SP792: A Multi-Center, Randomized, Double-Blind, Placebo-
Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and 
Safety of Four Different Transdermal Doses of Rotigotine in Subjects 
with Idiopathic Restless Legs Syndrome. 
Kyowa 6002-US-201: A Phase 2, Double-Blind, Placebo Controlled, 
Randomized Parallel-Group, Multicenter Study to Evaluates the Efficacy 
and Safety of 40mg/day KW-6002 (Istradefylline) in Subjects with 
Restless Legs Syndrome. 
Somaxon SP-OS03: A Phase III, Randomized, Double-Blind, Placebo 
Controlled, Parallel-Group, Multicenter Study to Assess the Long Term 
Efficacy and Safety of Doxepin HCI in Primary Elderly Insomnia Patients 
with Sleep Maintenance Difficulties. 
Takeda EC302: A Randomized, Double-Blind, Placebo-Controlled Study 
to Determine the Long-Term Efficacy and Safety of Ramelteon in Adults 
with Chronic Insomnia. 
Cephalon CI09S3/3046IES/uS: A Short-Term (8-Week) Open-Label 
Study, Followed by a Long-Term Evaluation, to Assess Patient Reported 
Outcomes with Armodafinil Treatment (ISO to 2S0 mg/day) for 
Excessive Sleepiness in Adults with Narcolepsy or Obstructive Sleep 
Apnea/Hypopnea Syndrome (OSAHS). 
200S GlaxoSmithKline 1001468/20S: A 12 Week, Double-Blind, Placebo-
Controlled, Parallel-Group Study to Assess the Efficacy and Safety of 
Ropinirole XR (Extended Release) in Patients with Restless Legs 
Syndrome. 
Takeda 01-04-TL-37 S-041: A Randomized, Double-Blind, Placebo 
Controlled Study to Assess the Subjective Response to Treatment with 
Ramelteon (TAK-37S) in Adult Subjects With Chronic Insomnia by 
Utilizing an Interactive Voice Response System (IVRS) for Collecting 
Diary Data. 
Neurocrine NBI-34060-MR-OS01: A Phase III, Randomized, Double-
Blind, Placebo Controlled, Polysomnographic Study to Assess the 
Efficacy and Safety of a Modified Release Formulation ofNBI-34060 in 
Primary Insomnia Patients with Sleep Maintenance Difficulties. 
Somaxon SP-OSOl: A Phase III, Randomized, Double-Blind, Placebo 
Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and 
Safety of Doxepin HCL in Primary Insomnia Patients with Sleep 
Maintenance Difficulties. 
2004-2007 Merck 002-00: A Double-Blind, Randomized, Placebo-Controlled, 
Multicenter, 30-Night Polysomnographic Study ofMK-0928 in Elderly 
Patients with Primary Insomnia 
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Oscient OS-OOl/FORCE: A Phase IV, Stratified, Randomized, 
Prospective, Unblinded, Active-Control Trial of Factive Versus Biaxin 
XL for the Treatment of Community-acquired Pneumonia and Versus 
Amoxicillinlclavulante for the Treatment of Acute Bacterial 
Exacerbation of Chronic Bronchitis. 
2004-2006 Merck 004-00: A Double-Blind, Randomized, Placebo-Controlled, 
Multicenter, 30-night Polysomnographic Study ofMK-0928 in Adult 
Patients with Primary Insomnia. 2004-2006. 
Cephalon, Inc. Cl0953/3024/ESIMN:A l2-Month, Open-Label, 
Flexible-Dosage (100 to 250 mg/day) Extension Study of the Safety and 
Efficacy of CEP-l0953 in the Treatment of Patients With Excessive 
Sleepiness Associated With Narcolepsy, Obstructive Sleep 
ApnealHypopnea Syndrome, or Chronic Shift Work Sleep Disorder. 
2004-2005 Altana Pharma BY2l7/M2-023: A Randomized, Controlled Study of 
Roflumilast (250 mcg and 500 mcg) Versus Placebo in Patients with 
Asthma. A 24-Week, Multicenter, Multinational, Double-Blind, Parallel 
Group Clinical Study. 
Cephalon Inc, CEP-10953 Cl0953/30211APIMN: A l2-Week, 
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to 
Evaluate the Efficacy and Safety ofCEP-l0953 (150 and 250 mg/day) as 
Treatment for Adults With Residual Excessive Sleepiness Associated 
with Obstructive Sleep ApnealHypopnea Syndrome. 
2004 Aventis MlO0907C/2004: A North American, 4-Week, Multicenter, Phase 
IIB Double-Blind, Placebo-Controlled, Randomized, Multiple Dose, 
Parallel-Group Study of the Efficacy and Safety of 0.5 mg, 1.0 mg, and 
2.0 mg M1 00907 Tablets in the treatment of Sleep Maintenance Insomnia. 
Sanofi-Synthelabo LTE5407: Evaluation ofthe Long-Term Efficacy and 
Safety of Zolpidem-MR 12.5mg Compared to Placebo, when Both are 
Administered Over a Long-Term Period "As Needed", in Patients with 
Chronic Primary Insomnia. (A Randomized, Double Blind, Placebo-
Controlled, Parallel Group, Multicenter, Phase IIIb Clinical Study). 
Pfizer A9001243: A Study To Define The Non-Restorative Sleep 
Population. 
GlaxoSmithKline 100013: A 12 Week, Double-Blind, Placebo 
Controlled, Twice Daily Dosing Study to Assess the Efficacy and Safety 
of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) 
Requiring Extended Treatment Coverage. 
2003-2004 Orphan Medical, Inc. OMC-SXB-22: A Randomized, Double-Blind, 
Double-Dummy, Placebo-Controlled, Parallel-Group, Multi-Center Trial 
Comparing the Effects of Orally Administered Xyrem (sodium oxybate) 
and Modafinil with Placebo in the Treatment of Daytime Sleepiness in 
Narcolepsy. 
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GlaxoSmithKline 101468/249: A 12 Week, Double-Blind, Placebo 
Controlled, Parallel Group Study to Assess the Efficacy and Safety of 
Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS). 
2003 Orphan Medical, Inc. OMC-SXB-15: A Randomized, Double-Blind, 
Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the 
Effects of Orally Administered Xyrem (Sodium Oxybate) with Placebo 
for the Treatment of Narcolepsy. 
Orphan Medical, Inc. OMC-SXB-19: An Open Label, Multi-Center 
Safety Trial studying the Effects of Orally Administered Xyrem (Sodium 
Oxybate). 
Takeda 01-03-TL-375-038: A Phase II Safety Study ofTAK-375 in 
Subjects with Mild to Moderate Chronic Obstructive Pulmonary Disease. 
Sanofi-Synthelabo EFC5202: Evaluation of the Hypnotic Properties of 
Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared 
to Placebo in Patients with Primary Insomnia. A Double- Blind, 
Randomized, Placebo-Controlled, Three Way Cross-Over Study. 
2002 GlaxoSmithKline 101468/191: A 12 Week, Double-Blind, Placebo-
Controlled Parallel Group Study to Assess the Efficacy, Safety and 
Tolerability of Ropinirole in Subjects with Restless Legs Syndrome (RLS) 
Suffering from Periodic Leg Movements of Sleep (PLMS). 
Sanofi-Synthelabo EFC4529: Comparison of Efficacy and Safety of 
Zolpidem-MR 12.5mg and Placebo in Patients with Primary Insomnia. A 
Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study. 
Neurocrine NBI34060-MR-0212: A Phase III, Randomized, Double-
Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess 
the Efficacy and Safety of a Modified Release Formulation ofNBI-34060 
in Elderly Primary Insomnia Patients with Sleep Maintenance 
Difficulties. 
Takeda 375-022: A phase III, Open-Label, Fixed Dose Study to 
Determine the Safety of Long-Term Administration ofTAK-375 in 
Subjects with Chronic Insomnia. 
GlaxoSmithKline 101468/243: A 52 Week, Open-Label Extension Study 
of the Long-term safety and tolerability of Ropinirole in Subjects 
with Restless Legs Syndrome (RLS). 
2001-2002 Sepracor 190-047: A Randomized, Double-Blind, Placebo-Controlled 
Parallel, Two-Week Objective Efficacy and Safety Study of Esopiclone 
in Elderly Subjects with Primary Insomnia. 
Takeda 375-005: An Efficacy, Safety, and Dose Response Study of 
TAK-375 in Subjects with Chronic Insomnia. 
2000 Sepracor 190-046: A Randomized Double-Blind, Placebo-Controlled 
Parallel Study of the Efficacy and Safety of (S)-Zopiclone in the 
Treatment of Adult Subjects with Primary Insomnia. 
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